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the national treatment agency for Substance misuse 
The National Treatment Agency for Substance Misuse (NTA) is a special health authority 
within the NHS, established by the Government in 2001 to improve the availability, 
capacity and effectiveness of treatment for drug misuse in England. 
Treatment can reduce the harm caused by drug misuse to individuals’ well-being, to public 
health and to community safety. The Home Office estimates that there are approximately 
250,000–300,000 problematic drug misusers in England who require treatment. 
The overall purpose of the NTA is to: 
•	� double the number of people in effective, well-managed treatment between 1998 
and 2008 
•	� increase the percentage of those successfully completing or appropriately 
continuing treatment year-on-year. 
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 1. Introduction 

Introduction – key points 
•	� The pharmacological management of substance misuse should be in line with the 
recommendations in the National Service Framework for Children, Young People and 
Maternity Services (2004). 
•	� The pharmacological management of substance misuse is only one component of 
addressing substance-related needs. 
•	� Pharmacological management of substance-related need should be based on a holistic 
assessment of the child or young person’s needs and tailored to those needs, not 
delivered as a ‘one model fits all’ programme. 
•	� Effective pharmacological management could reduce self-harm and suicidal 
behaviour. 
•	� Pharmacological management should be delivered alongside specific psychosocial 
interventions to provide comprehensive care for substance misuse. 
•	� Pharmacological management should be delivered alongside mental health services 
for those children and young people with mental health needs. 
•	� Pharmacological management should be delivered in the context of a clear clinical 
governance framework. 
1.1 national policy and guidance 
An organised, systematic and integrated approach to children and young people’s substance-
related needs across children’s services is desirable. This approach is inclusive, assessing and 
addressing all aspects of need of the child, with the help of parents/carers and close 
involvement of multi-professional agencies. This approach fits with the National Service 
Framework (NSF) for Children (Department for Education and Skills and Department of 
Health, 2004), which advocates services being designed and delivered around the needs of 
the child. The NSF for Children sets standards and advocates access to timely, high-quality 
multi-disciplinary services to ensure effective assessment, treatment and support for children 
and their families. All children’s and young people’s healthcare developments should be in 
keeping with the NSF. 
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Guidance	for	the	pharmacological	management	of	substance	misuse	among	young	people 
This guidance has been drawn together by the NTA under the direction of a panel of 
experts as a useful summary of the appropriate pharmacological treatment for substance 
misuse among young people under 18 years of age. The expert panel has drawn on the 
international research literature, relevant published guidance, and clinical experience and 
expertise. The following references are particularly important: 
1999 Young people and drugs: Policy guidance for drug interventions, Standing 
Conference on Drug Abuse and the Children’s Legal Centre (available from 
DrugScope) 
2004 Effective evidence based management of benzodiazepine withdrawal, British 
National Formulary 
2004 National Service Framework for Children, Young People and Maternity Services 
Executive Summary (and other NSF publications), Department of Health 
2007a Methadone and buprenorphine for the management of opioid dependence, National 
Institute for Health and Clinical Excellence (NICE) 
2007b Naltrexone for the management of opioid dependence, NICE 
2007c Community-based interventions to reduce substance misuse among vulnerable and 
disadvantaged children and young people, NICE 
2007d Drug misuse: Opioid detoxification, NICE 
2007e Drug misuse: Psychosocial interventions, NICE 
2007 0–18 years: Guidance for all doctors, General Medical Council 
2007 Assessing young people for substance misuse, NTA 
2007 Drug misuse and dependence: Guidelines on clinical management, Department 
of Health 
1.2 the care pathway 
A prerequisite of pharmacological management is a comprehensive assessment of the young 
person’s needs and risks to that young person, and the establishment of a care plan. 
Pharmacological management should be provided in conjunction with psychosocial 
interventions and support, including risk management tailored to the individual. Aftercare 
provision needs to be put in place, which includes psychosocial interventions to prevent relapse. 
A clear patient pathway reduces unnecessary delay and acts to improve patient safety. 
This can be achieved by good joint working and should include; practical support, 
counselling and treatment options as part of a care plan. Protocols should be developed 
for rapid information sharing across agencies, where this is necessary. 
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Introduction 
It is crucial that pharmacological and psychosocial substance misuse interventions are linked 
closely with all other services in the community that may be required, particularly with 
mental health services, in order that complex needs are assessed and comprehensively 
managed. Community-based services should develop relationships with local custodial 
facilities in order to encourage joint working and ensure continuity of care both to and 
from custodial establishments. 
Pharmacological approaches should be based on individually assessed need, and should not 
follow a ‘one size fits all’ model. The range of clinical responses specifically for substance 
misuse should include pharmacological approaches such as detoxification, stabilisation, 
reduction and maintenance regimes, with integrated psychiatric and/or psychological and 
physical care. Systems, policies and protocols should be in place to ensure that a care 
pathway is developed and followed across children’s services. 
1.3 Dependence 
This document has been written to provide guidance on the pharmacological treatment of 
substance misuse. This is mainly concerned with the management of physical dependence. 
Substance use, while a prelude to misuse, and increasing risk of dependence, is not per se 
sufficient for a diagnosis of dependence. The Tenth Revision of the International 
Classification of Diseases and Health Problems (ICD-10) defines the dependence syndrome 
as being a cluster of physiological, behavioural and cognitive phenomena in which the use 
of a substance or a class of substances takes on a much higher priority for an individual than 
other behaviours that once had greater value. A central descriptive characteristic of the 
dependence syndrome is the desire (often strong, sometimes overpowering) to take 
psychoactive drugs (which may or may not have been medically prescribed), alcohol or 
tobacco (World Health Organization, 2005). 
ICD-10 also states that: 
“A definite diagnosis of dependence should usually be made only if three or more of the 
following have been present together at some time during the previous year: 
•	� A strong desire or sense of compulsion to take the substance. 
•	� Difficulties in controlling substance-taking behaviour in terms of its onset, 
termination, or levels of use. 
•	� A physiological withdrawal state when substance use has ceased or has been reduced, as 
evidenced by: the characteristic withdrawal syndrome for the substance; or use of the 
same (or closely related) substance with the intention of relieving or avoiding 
withdrawal symptoms. 
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•	� Evidence of tolerance, such that increased doses of the psychoactive substance are 
required in order to achieve effects originally produced by lower doses (clear examples 
of this are found in alcohol- and opioid-dependent individuals who may take daily 
doses sufficient to incapacitate or kill non-tolerant users). 
•	� Progressive neglect of alternative pleasures or interests because of psychoactive substance 
use, increased amount of time necessary to obtain or take the substance or to recover 
from its effects. 
•	� Persisting with substance use despite clear evidence of overtly harmful consequences, 
such as harm to the liver through excessive drinking, depressive mood states consequent 
to periods of heavy substance use, or drug-related impairment of cognitive functioning; 
efforts should be made to determine that the user was actually, or could be expected to 
be, aware of the nature and extent of the harm.” 
Physical and psychological dependence should be addressed if treatment of substance use 
is to be successful. This document has been written to provide guidance on the 
pharmacological treatment of substance misuse, which is mainly concerned with the 
management of physical dependence. Nevertheless it is essential that access to support in 
managing psychological dependence is available. Such support is an essential part of the 
pharmacological management of substance misuse and is a credible intervention in its own 
right where pharmacological interventions are not required, as is the case in most substance 
misuse among young people. Guidance produced by NICE (2007c and 2007e) and the 
NTA (2008b) discusses evidence-based psychosocial interventions appropriate for young 
people with substance misuse needs. 
Physiological withdrawal symptoms and physical problems as part of the dependence 
syndrome are less frequent in adolescents than in adults. For adolescents it is important to 
enquire about craving and impulsive behaviours, anxiety, panic attacks, depression, feelings 
of despair and deliberate self-harm, as these may complicate identification and management 
of dependence symptoms. Poly-substance use, including alcohol, appears to be the rule 
rather than the exception; this is important in the assessment and management of possible 
withdrawal symptoms. It is also important to recognise that, in children and adolescents 
with substance dependence, other disorders such as disruptive disorders, conduct disorders, 
attention deficit hyperactivity disorder, post-traumatic stress disorder, anxiety, depression 
and eating disorders frequently co-exist. Knowledge of the assessment and management 
of these co-morbid disorders is essential for the adequate assessment and management 
of substance dependence. These co-morbidities and multiple problem presentations 
also emphasise the importance of multi-disciplinary assessment and care. 
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1.4 Drug-related deaths 
There has been much concern about drug-related deaths with the publication of the 
Advisory Council on the Misuse of Drugs (ACMD) Reducing drug related deaths report 
(2000), Drug misuse and dependence (Department of Health, 1999) and numerous research 
reports. As a consequence there is an emphasis placed on the importance of preventing 
drug-related deaths in local drug strategies. 
Deaths result from numerous problems such as infections, use of multiple drugs or suicide. 
One study (Krausz et al, 1996) reported that 8–17% of fatalities in heroin addicts were due 
to suicide. Initiatives to reduce drug-related deaths mainly focus on deaths associated with 
heroin and methadone. However, cocaine, alcohol, benzodiazepine and volatile substance 
misuse can also lead to death, especially when combined with opioids. 
Deaths occurring from methadone treatment occur mainly in the first few days, on average 
during the third or fourth day following initiation, generally as a result of accumulated 
toxicity. Methadone-related deaths are more often related to reduced tolerance to opioids, 
dose of methadone, especially in the naive user, and continued multiple illicit drug use. 
Fatalities from methadone toxicity have been reported at doses as low as 20 mg – though 
these have invariably been in non-opioid-dependent individuals who were poly-drug users 
(using benzodiazepines, alcohol, antidepressants or major tranquillisers). Non-opioid-
dependent individuals are at risk from doses as low as this, and their risk may be 
exacerbated with the simultaneous prescription of a benzodiazepine, antidepressants or 
major tranquillisers. These deaths have often occurred as a consequence of inadequate 
assessment, unclear tolerance, failure to confirm use and dependence, treatment in the 
absence of withdrawal symptoms and a lack of monitoring. Methadone-related deaths have 
reduced in the last few years, probably as a result of increased supervised consumption in 
the initial stages of drug treatment. However, caution is particularly important with young 
people who may have unclear tolerance. Assessment of this risk is crucial both in initiation 
and in monitoring methadone treatment, especially during the early stages. 
There is added concern about those who have just left custody; this concern is related to 
loss of tolerance. Singleton et al (2003) found that in the week following release prisoners 
were 40 times more likely to die than the general population and that 90% of these deaths 
were associated with drug-related causes. These findings are consistent with the 
international literature which suggests that overdose is common in those with lost or 
reduced tolerance. The ACMD (2000) gives guidance and numerous recommendations on 
issues such as risk assessment, information required, discharge arrangements and service 
delivery changes to ensure reduction of these deaths. 
Crucially, all young people leaving custody (and their parents/carers) should be given 
information and advice on drug-related deaths and their prevention and be considered for 
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priority access to young people’s specialist substance misuse treatment when returning to 
the community. 
1.5 ten key policy principles 
These principles, established by the Standing Conference on Drug Abuse and the 
Children’s Legal Centre (1999), inform substance misuse treatment services for children 
and young people. These overarching principles have been kept in mind throughout the 
production of this guidance and should continue to be referred to by practitioners 
implementing the guidance. They are based on the Children Act 1989 and the United 
Nations Convention on the Rights of the Child. 
1.	� A child or young person is not an adult. Approaches to young people need to reflect 
that there are intrinsic differences between adults and children and between children 
of different ages. 
2.	� The overall welfare of the child is paramount. 
3.	� The views of the young person are of central importance, and should always be 
sought and considered. 
4.	� Services need to respect parental responsibility when working with young people. 
5.	� Services should co-operate with the local authority in carrying out its responsibilities 
towards children and young people. 
6.	� A holistic approach should occur at all levels. 
7.	� Services should be child-centred. 
8.	� A comprehensive range of services should be provided. 
9.	� Services should be competent to respond to the needs of young people. 
10.	� Services should aim to operate in all cases according to the principles of good practice. 
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2. responsibilities
�
responsibilities – key points 
•	� Informed consent for treatment is required. 
•	� Informed consent should be gained from the appropriate person, either a competent 
young person or a parental responsibility holder. 
•	� While a child or young person has a right to confidentiality they should be 
encouraged to involve others in their care. 
•	� Confidentiality should be balanced against the duty to protect a child or young 
person from significant harm, so in some cases confidentiality may need to be 
breached. 
•	� All pharmacological management is subject to clinical governance arrangements and 
review. 
•	� Doctors and non-medical prescribers have a range of duties in relation to prescribing, 
particularly in relation to the treatment of substance misuse in children and young 
people, and these responsibilities cannot be delegated. 
•	� All staff involved in the assessment and pharmacological management of young 
people should be competent in the activities they are performing. 
•	� In the pharmacological management of substance misuse the use of medicines 
outside of their licence is often unavoidable. In this case proper precautions should 
be taken. 
•	� A range of protocols is required to ensure consistent good practice. 
•	� Information about the range of substance misuse interventions available in the 
establishment should be provided to young people and to parents/carers. 
•	� Careful and accurate recording of information about a young person’s assessment 
and treatment improves the understanding within the team and the quality of care 
for the young person. 
This chapter describes the essential responsibilities of medical and non-medical practitioners 
in relation to performing and monitoring the prescribing of medication and their 
responsibilities in relation to working with children, particularly adolescents. The General 
Medical Council (GMC) (2007) has given guidance on the issues of informed consent and 
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confidentiality for those working with young people under 18. It is incumbent on all 
practitioners to be aware of this advice, to assess competence and to be clear that full 
informed consent has been sought and freely given prior to any intervention. A young 
person may be anxious about obtaining treatment and due care should be taken to reassure 
them as well as giving full explanations of the treatment and the reasons for it. 
2.1 Informed consent 
When providing healthcare informed consent should be given before you can proceed, the 
only exception to this being a medical emergency. This is not only good practice but also a 
legal requirement. Informed consent should not be asked for or given until the treatment 
plan is proposed. Support and information are often required to help young people 
understand what they are being asked to consent to. To be legally valid, consent should be 
sufficiently informed, be specific to the treatment, and be freely given by a person who is 
competent to do so (Larcher, 2005). It may be helpful to use consent forms that are signed 
and kept in the clinical records, as consent should be recorded. 
Any change in pharmacological management should be carefully discussed and reasons for 
change carefully recorded, to ensure that consent is maintained. Anyone who gives consent 
can retract it at any stage in the treatment process if they wish. 
If a young person is not legally competent (does not have ‘capacity’) to give consent for 
themselves, consent will need to be gained from someone who has parental responsibility 
for them, unless it is an emergency and it would be unreasonable to wait. 
If a young person is competent to give consent for themselves, consent should be sought 
directly from them. The legal position regarding ‘competence’ is different for young people 
aged over and under 16. 
Young people aged 16 and 17 are presumed in law to be competent to give consent for 
themselves. However, it is still good practice to involve their families and/or carers in 
decision-making. 
Young people under 16 are not automatically presumed to be legally competent to make 
decisions about their healthcare. However, they may be competent if they can demonstrate 
that they are ‘Gillick’ or ‘Fraser’ competent. There is no specific age when a young person 
becomes competent; it will depend on the young person, their own development, and the 
seriousness and complexity of the treatment. It is still good practice to involve their families 
in decision-making. 
It should not be assumed that a young person with a learning disability is not competent to 
make their own decisions. Many young people with learning disabilities will be competent 
10 
  
 
 
 
 
 
 
               
 
 
Responsibilities 
provided that they are given appropriate information and supported through the process. 
However, if a young person is not thought to be competent, then the person with parental 
responsibility should make the decision for them, but the young person should continue to 
be involved as much as possible. 
Practitioners working with young people must have the skills and knowledge to assess this 
capacity to consent. 
2.2 assessing competence 
For young people to have the capacity (be competent) to take a particular decision (give or 
withhold consent), they should be able to comprehend and retain information relevant to 
the decision, especially as to the consequences of having or not having the intervention in 
question, and use and weigh this information in the decision-making process. 
2.2.1 Gillick or fraser competence 
Young people under 16 have a right to confidential medical advice and treatment if the 
provider assesses that: 
•	� the young person understands the advice and has the maturity to understand 
what is involved 
•	� their physical and/or mental health will suffer if they do not have treatment 
•	� it is in their best interest to be given such advice/treatment without parental 
consent 
•	� they will continue to put themselves at risk of harm if they do not have advice/ 
treatment 
•	� they cannot be persuaded by the doctor/health professional to inform parental 
responsibility holder(s), nor allow the doctor/health professional to inform them. 
If a child, or a young person under 18 years old, is not competent to consent to their own 
treatment, consent should be sought from a person with ‘parental	responsibility’. Legally, 
consent is needed from one person with parental responsibility, although it is good practice 
to involve all those close to the child in the decision-making process (see Appendix 1 for who 
holds parental responsibility). 
2.3 Confidentiality 
When discussing health and social circumstances with professionals it is reasonable to 
assume that a child or young person would expect that this information is kept confidential 
(as the information is not generally known to other people). Whenever a confidential 
11 
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relationship is entered into the boundaries of this confidentiality should be discussed with 
the young person so that they understand what it means and how and when information is 
likely to be shared. It is appropriate that information is shared between professionals acting 
to support a young person provided that the young person is aware when the information 
is gathered that it is not confidential and will be shared with those professionals involved 
in their care, or later their consent is gained to share information beyond that originally 
envisaged, for example gaining support from another service. 
The boundaries of confidentiality are: 
•	� Information about health or substance misuse will not be passed to other people 
without the young person’s consent; for example passing information to another 
service. 
•	� Confidential information will be disclosed to others if the child is suffering, or 
likely to suffer, significant harm; for example to promote and safeguard the 
welfare of a child. 
•	� Confidential information will be disclosed to others if another person is at risk 
of significant harm; for example another person is at risk or community safety 
is at risk. 
•	� Where concerns arise as a result of information given by a child it is important 
to reassure the child but not to promise confidentiality. 
•	� If confidential information is to be disclosed attempts should be made to 
communicate this to the child or young person, unless it is felt that this would be 
detrimental. The nature of this communication will also depend on the content, 
nature and seriousness of the concerns. 
Despite the right to confidentiality, it is often in children and young people’s best interests 
to have the support of their family, particularly in making and supporting decisions about 
their health and treatment. The Children Act 1989 therefore recommends that practitioners 
in contact with children should encourage them to involve their family/carers. In some cases 
this may not be in the child’s best interest, but this should not be assumed. 
Inter-agency collaboration is often required to assess and respond to the needs of vulnerable 
children and young people. Partnership working is a fundamental principle and is 
encompassed in the Children Acts of 1989 and 2004, and Working together to safeguard 
children: A guide to inter-agency working to safeguard and promote the welfare of children
(HM Government, 2006a). Developing links between services will enable coherent packages 
of care, but it is important to continue working with the child, and gain their consent 
to involve the family wherever possible. 
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What to do if you’re worried a child is being abused (HM Government, 2006b) gives more 
information on the procedures and legal issues in relation to aspects of child protection 
investigations. 
2.4 Governance 
Clinical governance is a term used to describe the systematic approach to monitoring and 
continuously improving the quality of clinical interventions. For doctors and professionals 
involved in substance misuse and clinical management there are a number of important 
elements: clinical effectiveness, competence and continuous professional development, team 
working, information management, patient, public and carer involvement, risk management 
and public health. The doctor and other healthcare professionals should be aware of and 
have considered these issues (Department of Health, 2007). These elements are a mix of 
both individual and organisational responsibilities, to ensure appropriate and effective 
systems necessary to meet good practice standards. The NTA (2008a) will shortly be 
publishing guidance on drug treatment and clinical governance recommendations. 
The GMC (2006) sets out principles and values on which good medical practice is founded. 
There is a wide range of guidance available from professional bodies (such as the GMC, 
Medical Royal Colleges, the Nursing and Midwifery Council and the Royal Pharmaceutical 
Society), the Department of Health (2007) and the NTA (2005). Prescribing governance 
and an adequate understanding of the law relating to prescribing are important. 
Clinicians working with drug misusers should be appropriately competent, trained and 
supervised. They should have annual appraisals, with evidence of competence, continuous 
professional development and regular audit. A supervisory framework should be in place 
with regular supervision and advice available. All professionals should be aware of the 
clinical governance framework and process within their workplace. A timely and regular 
audit cycle should be in place. For example, under the process of risk management, incident 
reporting, risk assessment and infections control, each constitutes a duty on both the 
individual and organisations, and may be audited to improve practice. Interventions should 
be provided consistent with national guidelines and in line with the evidence base. 
2.5 Prescribing responsibilities 
Drug misuse and dependence: Guidelines on clinical management (Department of Health, 
2007) notes the roles and responsibilities of doctors and non-medical prescribers when 
prescribing drugs. All of these roles and responsibilities apply to doctors and non-medical 
prescribers. 
The term ‘non-medical prescribing’ refers to the prescribing of medication by health 
professionals other than doctors and dentists, categorised by supplementary prescribing and 
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independent non-medical prescribing. The clinical governance requirements are similar to 
those of doctors (Department of Health, 2007). 
Clinical care should be in accordance with evidence-based practice and within the context 
of a clinical governance framework. Clinical supervision and access to programmes of 
continuous professional development that offer staff the ability to develop skills both in 
managing adolescents and in addressing substance misuse problems are important means 
of supporting high-quality clinical practice. All staff should be competent to fulfil their 
roles, and work within clear guidelines. 
Minimum	responsibilities	of	the	prescriber: 
•	� Prescribing is the responsibility of the person signing the prescription – this 
responsibility cannot be delegated. 
•	� Medical practitioners should not prescribe in isolation – a multi-disciplinary 
approach is essential. For example, doctors should work with the specialist young 
people’s service and be an active part of the assessment and care plan. 
•	� A prescriber should have a competent understanding of the pharmacology and 
clinical indications for use, dose regimes and therapeutic monitoring in young 
people. 
•	� A full assessment, in conjunction with other professionals involved, should be 
undertaken and treatment goals set. 
•	� The clinician has a responsibility to ensure that the person is prescribed the 
correct dose, both at induction and throughout treatment. 
•	� The interventions should be consistent with national guidelines and in line with 
the evidence base. Any deviation should be documented, with clear reasoning and 
appropriate supervision sought. 
•	� Supervised consumption is recommended for patients on initiation to 
pharmacological management, during the stabilisation phase, and after any 
relapse or instability. 
•	� The prescriber should liaise regularly with the dispensing pharmacist about the 
specific patient and the prescribing regime. 
•	� Clinical reviews should be undertaken regularly. 
•	� Thorough, clearly written records should be kept. 
•	� Consent to treatment with informed consent should be sought and aspects of 
confidentiality should be considered. 
Department of Health (2007) 
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Special	considerations	when	prescribing	for	children	and	young	people: 
•	� Informed consent should be appropriately sought and clarified for the specific 
treatment planned. 
•	� Any child protection concerns should be disclosed within the appropriate 
procedures and acted on. 
•	� Prescribing should be seen as an enhancement to other psychological, social and 
medical interventions. 
•	� Substitute prescribing should only be undertaken when there is convincing 
evidence of current dependence. 
•	� Specialist involvement is important for managing the substance misuse treatment 
of young people, and active supervision and support should be sought by 
generalists or those with less experience. This supervision should be part of the 
clinical governance requirements. 
•	� Practitioners should ensure that they have opportunities to discuss and review 
their work with colleagues to maintain good and up-to-date practice. 
•	� Prescribing of licensed medications outside of the product’s licence alters the 
prescriber’s responsibility; the prescriber should be aware of this responsibility 
and discuss issues with the patient and their parents/carers as appropriate. 
•	� Parents/carers should be informed about and aware of any medications that are 
prescribed, with the young person’s permission and continued involvement. 
The doctor, non-medical prescriber and the team should actively seek to involve 
the parents/carers (with consent from the young person). 
•	� Settings of treatment should be appropriate for the level of observation required. 
•	� Where withdrawal rating scales have been used action points arising from 
recorded symptoms should be recorded. 
2.6 Skills, knowledge and training 
All staff providing assessment and clinical management of substance misuse should be 
competent in the activities they are performing. Skills and knowledge in substance misuse 
work is described in the nationally recognised standards Drug and Alcohol National 
Occupational Standards (DANOS). There are standards for the training of specialist doctors 
from all the Royal Colleges as well as agreed standards on roles and responsibilities (Royal 
College of Psychiatrists and Royal College of General Practitioners, 2005). These standards 
should be used to develop job descriptions, appoint and appraise staff and professionally 
develop staff. Additional competences in working with children and adolescents are also 
published and should be utilised. These include National Standards for Youth Justice, 
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Health and Social Care Standards and forthcoming Children’s National Occupational 
Standards. 
Clinical supervision is an important means of supporting high-quality clinical practice. 
An annual appraisal for nurses and doctors should be delivered in accordance with advice 
from the Nursing and Midwifery Council, the Royal Colleges and the GMC respectively 
and in line with the clinical governance framework of the organisation. 
2.7 Licensing of medications 
In the United Kingdom, ‘licensed’ medicines are those that receive a marketing 
authorisation (previously called a product licence). Licensing arrangements are determined 
by the Medicines Act 1968 and are implemented through the Medicines and Healthcare 
products Regulatory Agency. For each medicine, the doses, indications, cautions, 
contraindications and side effects given in the British National Formulary (BNF) reflect 
those in the manufacturer’s data sheets or Summary of Product Characteristics. The BNF 
also indicates when a treatment recommendation is for the use of a medicine outside the 
licensed indication (off-label use) for that product. 
Absence of a licence does not necessarily mean the absence of evidence for the proposed 
interventions. Most medicines have been tested for safe and effective use only in the adult 
population; typically evaluation takes place between 18 and 65 years, with few medicines 
used in adults specifically licensed for use in the treatment of children. Medicines prescribed 
for a child that are not licensed for that age group or for their health problem are referred to 
as ‘off label’ and medicines that do not have a licence at all as ‘unlicensed’. 
Children are different from adults, their bodies metabolise medicines differently from those 
of adults, and young children respond differently from older children. Thus detailed care 
and attention needs to be applied when making prescribing decisions for children and 
young people, taking into account their age, weight and developmental stage (Department 
for Education and Skills and Department of Health, 2004). When making the clinical 
decision to prescribe these drugs, the risks and benefits of the treatment should be 
considered and fully documented. 
The informed use of unlicensed or off label medicines is often unavoidable if children are to 
have access to the most effective medicines. Both scenarios are quite common and allowed 
for in legislation if the medicine is prescribed by a registered prescribing professional. 
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The Medicines Act 1968 and its Regulations provide exemptions that enable professionals 
to use or advise the use of licensed medicines outside the recommendations for the licence, 
or to override the warnings and precautions given in the licence. In these circumstances, the 
prescribing professional should be able to justify this action in accordance with a 
respectable, responsible body of professional opinion. 
Information should be given to the young person and their parents/carers on the nature of 
the drug to be used, the likely effect, the timing of this effect and the safety and licensing of 
the medication. It would be useful if this information is available in leaflet form as well as 
discussed verbally. Any difficulties in literacy skills need to be acknowledged. 
This information is important for a number of reasons: 
•	� young people need to feel that their dosage adjustments are for their own comfort 
and safety, rather than any punishment system 
•	� to ensure that informed consent can be given 
•	� to facilitate understanding of treatment given including likely outcomes. 
Primary care and health trusts, prescribers, dispensers and those administering medicines 
should take precautions to ensure that the use of off label or unlicensed medications is 
managed properly. There should be local safety standards and arrangements in place to 
monitor the use of unlicensed and off label medicines. 
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markers of good practice in the prescribing of medication 
National Service Framework for Children, Young People and Maternity Services: Medicines
(Department for Education and Skills and Department of Health, 2004) 
1.	� The use of medicines in children is based on the best available evidence of clinical 
and cost-effectiveness and safety, ideally derived from clinical trials, but also 
including, where appropriate, medicines that are not licensed for their age group or 
for their particular health problem (‘off-label’), or those that do not have a licence 
at all (‘unlicensed’) in order to achieve the best possible health outcomes and 
minimise harm and side effects. 
2.	� In all settings and whatever the circumstances, children and young people have 
equitable access to safe, clinically and cost-effective medicines in age-appropriate 
formulations. 
3.	� Appropriate information and decision support is available for professionals who 
prescribe, dispense and administer medicines for children and young people. 
4.	� Children, young people and their parents/carers receive consistent, up-to-date, 
comprehensive, timely information on the safe and effective use of medicines. 
5.	� In all settings, professionals enable parents, young people and, where appropriate, 
children to be active partners in the decisions about the medicines prescribed 
for them. 
6.	� Primary Care Trusts, NHS Trusts and other organisations ensure that the use of 
medicines in children is incorporated in their clinical governance and audit 
arrangements. 
7.	� The contribution of pharmacists in the effective and safe use of medicines in 
children is maximised. 
2.8 Licensed medications for the management of substance misuse 
The following is a list of the current licensing arrangements for medications used in the 
management of substance misuse: 
•	� Acamprosate is licensed from 18 years upwards. 
•	� Buprenorphine is licensed from age 16 for those with opioid dependence. 
•	� Bupropion is not recommended for those under 18 years. 
•	� Dihydrocodeine is not licensed for the treatment of dependence and is not 
recommended. 
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•	� Lofexidine is licensed from age 18 for use in those with opioid dependence. 
•	� Methadone is not licensed for children. ‘Children’ in this context is generally 
recognised to mean those aged 13 and younger; however, manufacturers note the 
lack of evidence for adolescents. 
•	� Naltrexone is licensed for post-opioid detoxification for those over 18 years, 
but it is not licensed in management of relapse prevention for alcohol misuse in 
the UK. 
•	� Nicotine replacement therapies are licensed from 18 years upwards. 
2.9 Protocols 
Ensure that good practice is standardised in a specific setting by the development of audited 
local policies and protocols. There should be active involvement of all staff in developing 
protocols. These should be based on evidence of good practice, and help to improve clarity 
of roles and responsibilities and understanding of these roles between different members of 
staff. Many of these protocols will already be available but it is important that staff are 
properly inducted in them and that they are regularly reviewed. 
Protocols are required for: 
•	� assessment 
•	� prescribing 
•	� obtaining consent to treatment/consent forms 
•	� sharing of information, confidentiality and involvement of parents/carers 
•	� child protection concerns 
•	� overdose management and prevention 
•	� supervised consumption of medication. 
This list is not exhaustive. A timely and regular audit and review cycle of all protocols and 
standards should be in place. 
All services should have written information available on the process of assessment, the 
types of pharmacological and psychosocial treatments available, how these interventions 
work, and how parents are involved in these processes. 
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This written information should be accessible to young people, physically available and 
written in a style that they can understand. It can include: 
• choice and length of treatments 
• consequences of untreated withdrawal, both physical and psychological 
• potential benefits of seeking help 
• risks of overdose and how to prevent overdose. 
Written information should be discussed with an individual considering engaging in 
treatment, to ensure their understanding of the written word and the content of the 
documents. Written information may be required in different languages and formats 
appropriate to a range of abilities to understand it. 
2.10 Data collection 
Providers of services should be prepared to establish comprehensive data collection and 
monitoring systems. Careful and accurate records need to be kept on assessment of the 
young person, their ability to consent, the involvement of parents/carers, the reasons for and 
goals of treatment, and outcomes. A copy of the care plan should be available for the young 
person and their parents/carers where the parents/carers are participating in it. Accurate 
record keeping improves understanding within the team and the quality of care for the 
young person. 
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3. assessment of substance 
misuse 
assessment of substance misuse – key points 
•	� The key features of identification and comprehensive assessment are: 
–	� assessment is an overall part of care 
–	� assessment is an ongoing process 
–	� the young person and their parents or carers should be encouraged to participate 
–	� the goals and process of assessment should be clear. 
•	� Key issues to be addressed at the pharmacological assessment are: 
–	� ascertain substance dependence, substance use history, route of use and 

inspection of any injecting sites
�
–	� positive urine/oral fluid screen for drug of dependence 
–	� identification of objective withdrawal symptoms 
–	� corroboration of reported current prescribed medication 
–	� ascertain urgent physical health difficulties 
–	� ascertain any risk of suicide, self-harm or psychiatric difficulties 
–	� identification of pregnancy. 
•	� Comprehensive assessment of substance misuse should include: 
–	� involvement of the young person, to discuss and assess their physical health, 
injecting behaviour, mental health and social factors related to substance misuse 
behaviour 
–	� conducting any necessary invasive investigations such as drug screens, blood tests 
for infectious diseases, pregnancy etc 
–	� parental/carer involvement 
–	� community substance misuse service involvement. 
•	� Comprehensive assessment of substance misuse will often involve a multi-disciplinary 
approach. 
•	� Comprehensive assessment will include assessment of all domains of functioning 
both antecedent and current, e.g. mental health, risk and educational ability. 
•	� Assessment should be used to formulate a care plan of treatment interventions, 
each of which requires informed consent from the appropriate person before they 
can commence. 
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Galahad (2004) reported that many young people seemed uneasy about disclosing drug use. 
Barriers to appropriate disclosure such as lack of treatment, perception of lack of treatment 
or lack of skill of the assessor should be overcome. Information, in both written and oral 
form, should be provided during assessment about the treatment options available, both in 
the short term and the long term. Should dependence or problems related to substance 
misuse be noted, reassurance should be given that services are available to support the 
individual and their parent/carer. 
Presenting a non-judgemental, reassuring attitude helps to establish rapport and good 
communication, which facilitates engagement with the assessment and treatment process. 
In addition, assessment should take account of the young person’s cultural background and 
their cognitive, language and emotional development. 
It is common for substance users to use local slang or terms for substances and routes of 
administration; these differ from region to region and change rapidly. It is important to 
clarify what substances are being used and how they are taken by checking with the young 
person, rather than guessing their meaning. The same slang name is often used in different 
areas for different substances. 
Good assessment is crucial for the continuing care of the young person. It is essential in the 
development of a comprehensive care plan and the review of this care plan. Assessment is an 
ongoing process that should be updated fully and regularly. Comprehensive assessment is 
likely to take several sessions to complete in order to organise a full care plan. It is essential 
that there is accurate documentation of this assessment in the young person’s case records. 
The rest of this chapter describes specific elements of the assessment process. 
Key	principles	of	identification	and	comprehensive	assessment	process: 
•	� Assessment is an overall part of care. 
•	� Assessment is an ongoing process. 
•	� Assessment should be comprehensive, including all aspects of risk and child 
protection. 
•	� The young person and their parents/carers should participate. 
•	� The goals and process of assessment should be clear. 
22 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessment	of	substance	misuse 
The	essential	aims	of	substance	misuse	assessment	are: 
•	� to treat any emergency situation 
•	� to confirm drug and alcohol use or misuse 
•	� to determine if there is a physical dependence and need for a pharmacological 
response 
•	� to ascertain complications of drug and alcohol use/dependence 
•	� to ascertain other mental health needs 
•	� to ascertain other physical health needs 
•	� to ascertain social factors that are associated with substance misuse such as offending 
behaviour, peer group and exploitation 
•	� to ascertain psychological problems related to substance use, such as anxiety or 
behaviour disorders 
•	� to ascertain child protection needs and the involvement of parents/carers 
•	� to assess educational abilities and needs 
•	� to ascertain highly risky substance use behaviour and give appropriate advice on 
harm reduction, including overdose risk, risk of injecting, risk of exposure to 
blood-borne viruses and risky sexual behaviour 
•	� to ascertain the risk of hepatitis, blood-borne viruses, sexually transmitted diseases 
or pregnancy 
•	� to offer immunisation to hepatitis B 
•	� to ascertain capacity to consent to treatment. 
3.1 Pharmacological assessment of substance misuse 
Where a young person has presented for substance misuse treatment and there is an 
indication that a pharmacological response is required, a pharmacological assessment should 
be undertaken as soon as possible to precipitate an urgent intervention. Doctors and non-
medical practitioners are encouraged to work closely with a young people’s specialist 
substance misuse service during pharmacological assessment, to ensure that they are not 
working in isolation and are involved in the comprehensive assessment of substance misuse. 
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In order to determine whether a pharmacological treatment response is required physical 
dependence should be identified. This is determined primarily by a history of daily use of a 
substance for some time, the presence of withdrawal symptoms on cessation of use of the 
substance (these symptoms emerging within the timescale expected for that substance) and 
a relief of these withdrawal symptoms on reinstatement of consumption of the substance. 
The treatment of withdrawal symptoms will act to reduce the risk of self-harm and 
complications associated with withdrawal from alcohol and drugs. 
Severe withdrawal phenomena can occur, e.g. alcohol dependence with withdrawal may 
cause seizures or delirium states, and for benzodiazepines seizures can occur. Opioid 
withdrawal may present with physical problems of increased sweating, diarrhoea and/or 
marked anxiety and agitation. Severe withdrawals or the consequences of withdrawal 
(e.g. delirium tremens) can in rare cases lead to fatalities. Where withdrawal symptoms are 
present a more detailed assessment and commencement of substitute medication may 
be required to ensure the provision of adequate and effective management of withdrawal 
symptoms on the first night in custody. 
Substance use can be associated with mental health problems such as psychosis, either causal 
(drug induced) or aggravating existing psychotic symptoms. The presence of significant 
mental health symptoms such as psychotic symptoms or self-harm and suicide risk should 
precipitate an urgent mental health assessment. 
The key issues to be addressed in the pharmacological assessment are: 
•	� to ascertain drug and/or alcohol dependence, substance misuse history, route of 
use and inspection of injecting sites 
•	� positive urine/oral fluid screen for the particular drug(s) of dependence 
•	� identification of objective withdrawal symptoms 
•	� ascertain corroboration of reported current prescribed medication either for 
substance misuse or other health issues 
•	� urgent physical health related difficulties 
•	� risk assessment: of suicide, of self-harm, of violence, or of psychotic or other acute 
psychiatric difficulties (urgent action should be taken to reduce these risks where 
they are identified) 
•	� identification of pregnancy – all females should be offered and encouraged to 
accept pregnancy tests prior to prescribing medication, with a full explanation of 
the reasons for the test. 
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Establishing clear evidence of substance use is required prior to prescribing any substitute 
medication. Therefore a drug toxicology test should be undertaken, though a positive result 
does not necessarily denote dependence. A range of withdrawal rating scales are available 
that can help with determining physical dependence, including: 
•	� Clinical Opiate Withdrawal Scale (COWS) (Wesson and Ling, 2003) 
•	� Clinical Institute Assessment of Withdrawal – Benzodiazepines (CIAW-B) (in 
Baillie, 1996) 
•	� Alcohol Withdrawal Syndrome (Bayard, McIntyre, Hill and Woodside, 2004). 
However, while the use of formal rating scales may be helpful, they should be considered as 
an adjunct to, but not a substitute for, clinical assessment (NICE, 2007d). 
Where a young person reports that they have been undertaking a pharmacological 
intervention by another service provider it is recommended that this treatment is continued. 
However, to be safe, it is clearly imperative to corroborate the prescription and compliance 
with treatment. Information required includes: 
•	� name of medication 
•	� dose including concentration of medication 
•	� whether consumption was supervised and by whom 
•	� compliance with the regime (including collection and consumption of medication 
where appropriate) from the previous service provider. 
Where corroborative information cannot be gained, including both the prescription and the 
consumption of the prescribed medication (essentially confirmed supervised dispensing), it 
is unsafe to prescribe based on a young person’s report alone. Drug toxicology and evidence 
of withdrawal signs will be required. Medication should also be re-titrated to ensure that the 
appropriate dose is administered. Please refer to later chapters which describe the induction 
process for specific medications. 
3.2 Comprehensive assessment of substance misuse 
This section describes the comprehensive assessment process of which pharmacological 
assessment is but one element. It can take some time to complete a comprehensive 
substance misuse assessment so it is likely to take place over several sessions. It may be 
that some interventions are commenced prior to full completion of this comprehensive 
assessment. 
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3.2.1 Interview with the young person 
The main feature of an assessment is the interview with the young person. It is vital that 
they are allowed the opportunity to contribute fully to this in order to establish a clear 
picture of the young person’s life, including substance use and how it directly and indirectly 
impacts on their life. The following factors should be covered in the interview. 
a)	 Review	of	substance	use	behaviour 
It is important to establish the quantity, frequency, route of administration, age of initiation 
and progression of substance misuse, and the types of substances used. This helps to define 
the level and severity of substance misuse/dependence and the risk factors associated with 
use. The pattern of young people’s substance misuse may be quite sporadic with little 
regularity of use. This irregular use may have prevented the development of physical 
dependence but there may still be problems related to substance misuse that need to be 
addressed. The type of substance, the route of use and the age of initiation can be indicators 
of current or future problematic substance misuse. 
b)	 Risk	assessment 
The multi-disciplinary team should assess and act on risks in relation to: 
•	� mental health, such as self-harm, suicide and psychotic thinking 
•	� violence to self and others 
•	� physical health, such as overdose, sexual health difficulties and physical problems 
related to drug use such as abscess, infections and injecting by sharing drug-
taking equipment 
•	� child protection – any concerns about risk should be dealt with urgently 
according to local policy and procedure. 
Those who use opioids are at a greatly increased risk of death during the first week of 
release from prison (Singleton et al, 2003). The predominant cause of these deaths is 
accidental drug overdose; the most likely cause is the loss of tolerance to opioids often 
complicated by the use of other drugs such as benzodiazepines and alcohol. Therefore 
advice and education on overdose prevention and seamless transfer of substance misuse 
treatment to a community team are vital, including arrangements for continued, regularly 
supervised pharmacological care where required. 
c)		 Context	of	use 
Commonly young people take substances with their peers. Having family members with 
substance misuse problems increases the likelihood of the young person developing 
substance misuse. Some young people become involved in substance misuse because they 
are being exploited by others, criminally and/or sexually. 
26 
  
 
 
 
 
 
 
 
 
 
 
 
Assessment	of	substance	misuse 
d)		 Factors	contributing	to	vulnerabilities	and	resilience	 
This aspect may demonstrate how the young person is getting on in school and with their 
family, and general social functioning, including offending behaviour. Young people may 
have poor insight into how substance use affects these aspects of their life. Understanding 
how a young person functions socially can be used in psychosocial support to explore the 
relationship with substance misuse and help to develop insight. Factors that support 
resilience to substance misuse, where they exist, should be encouraged and built upon. 
Vulnerability to substance misuse includes children who: 
• are ‘looked after’ or supervised by the local authority 
• are excluded from or disaffected with school 
• are involved in offending behaviour 
• have mental health difficulties 
• are homeless or local authority care leavers 
• are living in difficult family circumstances, including those subject to abuse 
• have drug- or alcohol-misusing parents 
• have physical or learning disabilities 
• are living in areas where there is a high availability of drugs. 
Resilience to substance misuse includes: 
• a positive temperament and intellectual abilities 
• a supportive family environment 
• a caring relationship with at least one adult 
• external systems of support that encourage positive values. 
(ACMD, 2006) 
e)		 Young	person’s	view	of	substance	use 
It is important to allow the young person to explore the advantages and disadvantages of 
their substance misuse from their perspective. This allows the assessor an opportunity to 
develop a rapport with the young person, as well as understand triggers, negative aspects 
and social reinforcers of substance misuse from the young person’s perspective. 
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f)	 Injecting 
Injecting is not common among young people but it is important to be alert to the 
possibility. Injecting drugs increases the risks to a young person, for example from overdose 
and blood-borne viruses; in addition injecting technique may be poor, which further 
increases risks. 
Injecting drug misuse carries a substantial risk of physical complications, particularly with 
sharing of drug-using equipment. Assessment should elicit information on exposure to 
blood-borne viruses, and lead to appropriate referrals. Those who inject substances are 
particularly at risk from viral hepatitis (A, B and C), HIV, bacterial endocarditis, 
septicaemia, deep vein thrombosis, pulmonary embolism, abscesses and thrombophlebitis. 
Assistance should be given to help the young person to engage with needle exchange services 
and to consider testing for hepatitis and initiate vaccination for hepatitis A and B. For those 
under 16, information on viral hepatitis and other blood-borne viruses should be discussed 
with the young person and their parents/carers whenever possible, preferably supported by 
written information. 
The Department of Health and Department for Education and Skills (2004) recommend 
that all intravenous drug users and close household contacts of intravenous drug users 
receive hepatitis B vaccinations. Vaccination should be commenced as early as possible, 
with accelerated programmes offered for hepatitis B following consent. If a young person 
has been held in a custodial establishment, such as a Young Offender Institution or a Secure 
Training Centre, they may have already commenced or completed a hepatitis B 
vaccination programme. 
Information and discussion should be offered to all intravenous drug users about hepatitis C 
virus and HIV testing. It is especially important to involve parents/carers in the process 
wherever possible as a positive test result will have lifelong implications. Time should be 
allowed to take on board the information and make a decision about whether to proceed 
with testing. Pre- and post-test counselling should be given, by a person with the skills and 
knowledge to help a young person to make an informed decision. 
g)	 History	of	treatment 
Some young people will have previously been involved in substance misuse treatment. 
Exploring periods of reduced use or abstinence and how this was achieved, as well as their 
perceptions of treatment, can help to develop a care plan that the young person feels 
confident with. 
Recent previous service providers that have been involved with the young person should be 
involved wherever possible, including services provided in a custodial setting and in Child 
and Adolescent Mental Health Services (CAMHS). This will help to provide a co-ordinated 
continuation of pharmacological or psychological support. 
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h)	 Physical	health 
Children and young people who misuse substances should have a physical examination. 
Primarily this is to establish a baseline of the health and development of the child/young 
person: this will include height and weight, any breathing difficulties or other health 
problems related to substance misuse, or other unmet healthcare needs. 
Height and weight measurements should be used to calculate the Body Mass Index (BMI). 
If a pharmacological intervention is to be considered the dose of the drug to be prescribed 
should take account of the BMI as currently evidence for drug prescribing is only available 
for adults. In all cases the dose should be titrated according to withdrawal symptoms; 
however, because there is little evidence about dose in younger people, particular caution 
should be applied when working with young people with low body weight. Consideration 
should always be given to the physical and mental development of all younger persons. 
Sexual health risks should also be considered and assessed, with a range of interventions 
available, such as chlamydia screening, hepatitis screening and vaccination, or other sexually 
transmitted infection risks. This may mean referral to and/or discussion with community 
clinics. Pregnancy should always be considered, and women should be encouraged to take 
a pregnancy test prior to any medication for substance misuse being prescribed, with 
an explanation of why this is required. 
Those who use substances are more at risk of developing a number of medical conditions 
such as pneumonia, asthma, tuberculosis, dental caries, seizures and other neurological 
impairments. Many of these physical manifestations of substance misuse may not yet be 
present in the young person; nevertheless, one should always be alert to possible 
complications of substance use. 
The risk of infectious diseases should be assessed, particularly HIV and hepatitis B and C. 
These infections are related to a history of sharing injecting equipment and/or risky sexual 
behaviour. Counselling and testing should be available, with full consent obtained and 
parental involvement as appropriate. 
Ongoing close clinical monitoring of physical health needs is important as the early 
symptoms of drug withdrawal may mask a separate underlying physical condition. 
i)	 Mental	health 
Young people who misuse drugs or alcohol often have co-existing psychiatric disorders and 
psychological difficulties that may affect their ability to engage with services, increasing the 
risk of relapse and poor compliance with treatment. These psychiatric conditions often 
co-exist alongside episodes of self-harm and suicidal behaviour. They may include conduct 
disorder, depression, post-traumatic stress disorder, anxiety, attention deficit hyperactivity 
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disorder or early psychosis. Young people may be receiving treatment from CAMHS in the 
community, and this requires assessment and confirmation. 
Drug or alcohol use may directly affect mental health, particularly causing paranoid 
ideation, hallucinations, anxiety and depression that may mimic some withdrawal 
symptoms. One should also be alert to withdrawal symptoms from nicotine withdrawal 
that may complicate mood and anxiety disorders. It is essential that these psychiatric and 
psychological problems are assessed. Ongoing monitoring of mental health is essential if 
there is any concern about, or any history of, psychiatric or psychological difficulties. 
A history of drug or alcohol overdose should also prompt an assessment of mental health. 
While most substance misuse overdoses are considered to be accidental, the possibility of 
suicidal intent should always be considered. 
3.2.2 Parental involvement 
Every effort should be made to involve parents or carers in the assessment and treatment 
of substance misuse, as involvement is most often beneficial. However, the possibility of 
difficulties arising from parental involvement should also be considered. There may be 
issues in relation to parents’ own drug or alcohol use, their mental health or their fear of 
judgemental attitudes. Families will almost always need support to engage them in their 
child’s care. However, the potential benefits should encourage this approach. 
It is important to remember that children and young people are entitled to confidentiality 
so contact with families should only be made with their explicit consent (see Section 2.3). 
The parent/carer’s role in the assessment of the child’s difficulties should include: 
•	� history of presenting problems with details of substance use 
•	� behaviour associated with substance use 
•	� onset and progression of co-morbid psychiatric, psychosocial and behavioural 
problems 
•	� treatment history 
•	� developmental history 
•	� medical history, e.g. accidents and possible head injuries 
•	� school and vocational history 
•	� peer relationships 
•	� family history, e.g. significant events, such as divorce or bereavements. 
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3.2.3 Invasive investigations 
An invasive or physical examination cannot be conducted without consent from the young 
person or parental responsibility holder (see Section 2.1). Some invasive investigations may 
be required as part of a comprehensive assessment. This would include drug toxicology 
prior to and during the prescribing of substitute medication, and blood tests to investigate 
health disorders. 
Tests for disorders such as hepatitis B and C and HIV that may have a lifelong impact 
should be conducted only in conjunction with pre- and post-test counselling by a skilled 
and knowledgeable practitioner. All young people who inject substances, share drug-using 
equipment/paraphernalia or engage in risky sexual behaviour should be considered for 
counselling and possible testing. 
Blood tests generally comprise: 
• liver function tests 
• full blood count 
• tests for hepatitis (A, B and C) and HIV. 
Drug testing can be a useful tool in assessment and in monitoring compliance with and 
outcomes of treatment. Prior to providing pharmacological interventions, a drug toxicology 
test is vital for establishing current use. This is to confirm self-report of opioid or 
benzodiazepine use and the use of other drugs that may complicate the presentation and 
management. Drug toxicology is also used to monitor ongoing treatment. 
The clinician should be aware of detection time of the various drugs in urine or oral fluid, 
be able to interpret the findings and be aware of false positive and negative results. Urine 
testing has the advantage that drug concentrations are higher and the window for detection 
is longer, which can be important where young people have been held in police custody for 
some time. Oral fluid, while less invasive to collect and harder to adulterate, will provide 
results only on very recent drug use (24–48 hours) (Department of Health, 2007). 
While it is essential to conduct a drug toxicology test prior to prescribing, the clinician 
should be aware that the results are generally qualitative and do not confirm dependence. 
However, the clinician should not usually prescribe substitute drugs if a urine/oral fluid test 
is negative, and/or in the absence of clinical withdrawal signs. 
In some cases a drug toxicology test does not detect opioids or benzodiazepines even when 
there is a history of regular use. This may happen due to the detection time of a drug or the 
sensitivity of a test. This situation should be treated with extreme caution, and clear 
withdrawal symptoms should be detected before continuing with substitute medication, and 
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a non-substitute, safer alternative may be preferred. It is more likely that the person is not 
physically dependent if the drug toxicology test is negative and there are no current 
withdrawal symptoms. A clinician may need specialist support and advice if they are still 
considering prescribing on such occasions. Further reading about drug toxicology can be 
found in Department of Health (2007). 
Protocol for drug toxicology 
Assessment	– urine sample for analysis taken in a thermal pot to help to ensure that it is 
actually the patient’s sample should be tested immediately. This test or an oral fluid 
sample should always be subject to a confirmatory test from a laboratory. However, 
treatment may need to begin prior to the confirmatory test result. 
Ongoing – urine sample for analysis collected in a thermal pot or oral fluid is 
recommended. These tests throughout treatment can be subject to immediate testing, 
but should also include some laboratory confirmatory testing. 
Urine	drug	analysis – for urine tests it is important that the clinician is sure that the 
sample belongs to the individual. Supervised urination may be appropriate in some 
circumstances though it can be conducted only with consent. It can be seen as 
humiliating; it is not always practical and is generally not acceptable for those under 16. 
Numerous techniques are available that can avoid the need for supervised collection, such 
as checking the temperature of the urine in thermal cups, and the use of more sensitive 
dipsticks. Dipsticks can be especially useful when immediate results are required. 
However, temperature and dipsticks can still be tampered with. Laboratory testing should 
be conducted to confirm initial immediate results and to support ongoing monitoring of 
compliance. Confirmatory laboratory tests are more reliable than screening tests. These 
screening tests are quick and easy and negative results can usually be accepted as such. 
However, positive results should normally be confirmed. 
Oral	fluid	drug	analysis – these are useful as they can be easily supervised. They ensure 
certainty that the sample belongs to the correct young person and a result is often 
available immediately. However, the immediate results are not as sensitive and the 
window of detection of positive and negative results is much shorter than urine tests, 
which can be problematic if the young person has been held in custody. 
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3.2.4 Capacity to understand the treatment and give informed consent 
During and following the assessment, proposals will be made to the young person about the 
intended course of interventions. At this stage consent will need to be gained from either 
the young person or the parental responsibility holder for any invasive investigations 
(such as urine analysis) and each proposed treatment intervention, psychological and 
pharmacological (see Section 2.1). 
Consent cannot be requested nor competence to consent assessed (in order to allow a young 
person to consent themselves) prior to the proposal of an intervention. It is impossible to 
give informed consent or to be competent to do so if no one has yet explained the 
treatment that consent is required for. 
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�
Care planning – key points 
•	� Substance misuse should not be managed in isolation from the holistic management 
of the child or young person. A multi-disciplinary approach should be taken. 
•	� A care plan with clear goals, agreed with the young person, should be developed and 
regularly reviewed. 
•	� Parents and carers of young people should be actively encouraged to participate in 
the young person’s care plan, with consent from the young person. 
•	� Careful discharge planning should be in place to ensure continuity of care 
from universal and targeted services in the community and custodial healthcare 
as appropriate. 
Effective substance misuse treatment and interventions to reduce the harm associated with 
substance misuse are best achieved in a culture of support, warmth and non-judgemental 
care, one that expects positive change and encourages individuals to make efforts to change. 
Alcohol and drug problems should not be managed in isolation, either from one another 
or from the comprehensive management of the young person. The findings of numerous 
studies report the high prevalence of substance misuse and the common co-occurrence of 
co-morbid disorders with the need for greater integrated planning and management 
(Gilvarry, 2000; Health Advisory Service, 2001; Galahad, 2004). 
When addressing substance misuse it is important that all aspects of functioning are 
considered and assessed: educational needs, emotional needs, physical health, mental health 
and substance misuse as well as any child protection concerns or risk issues such as 
self-harm, suicide and violence. The co-ordination of multi-disciplinary involvement may 
be required and if this is so it should be undertaken by a lead professional as outlined in 
NTA (2007). 
All interventions including pharmacological management should be evidence based and not 
just operated on an ‘it feels right’ principle. Interventions should be consistent with national 
guidance and principles (Department of Health, 2007). If there is little evidence for the 
intervention, then it should be delivered according to the best empirical principles available 
34 
  
 
 
 
 
 
 
 
Care	planning 
with clear evaluation and review processes established. All programmes should reflect the 
developmental needs of the children and young people in the setting, including their 
educational, language and emotional development. There will need to be particular 
consideration of aspects of programmes for those with learning disabilities. 
As the initial induction and monitoring of the pharmacological intervention is proceeding, 
it is essential that there is further in-depth and comprehensive assessment of all risks and 
needs of the young person to ascertain all substance-related problems and other 
psychological, emotional and educational difficulties. A full care plan with clear goals should 
then be established and agreed with the young person, with the involvement of their 
parents/carers, if this is appropriate. All aspects of the care plan then need to be monitored 
and regularly reviewed. 
4.1 Parental involvement 
The following section relates to parents, carers or guardians. 
As with the assessment process parent or carer involvement in the care planning and 
review process should be encouraged. An ethos of good communication and expectation of 
routine involvement at intervals throughout the treatment should be promoted. A proactive 
approach should be encouraged. Parents (with consent from the young person) should be 
invited to all meetings; of particular importance would be their involvement in care 
planning and discharge planning sessions with their child. 
Communication methods should be established with parents; mobile phone and landline 
numbers, grandparents’ numbers and email addresses should be obtained as appropriate to 
the young person’s circumstances as soon as possible. These contact details can then be 
stored in case files (with consent) to facilitate contact. 
There are a number of reasons for the involvement of parents, including: 
•	� to ensure appropriate parental responsibility for the child 
•	� parental responsibility holder consent may be needed for treatment for some 
children and young people 
•	� to give information to the parent/carer on the range of interventions and the 
specific interventions required for their child 
•	� to improve communication with the young person 
•	� to reframe anxieties for parents/carers and young people 
•	� to provide sources of support for children and young people 
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•	� to seek help and support for those parents/carers with substance use problems 
or mental health difficulties 
•	� to seek help and support for families with difficulties 
•	� to help to monitor compliance with medication. 
Some children may not be involved with either of their parents. In such cases active 
involvement from any responsible adult who has a relationship with the child should be 
encouraged. This may include a social worker, an older friend or a mentor. Evidence 
suggests that a caring relationship with at least one adult can be a protective factor to reduce 
the risk of development of substance misuse problems. 
Common themes of these sessions should be relapse prevention and management, harm 
reduction techniques, overdose prevention, and continued motivational work after the 
completion of treatment for both the young person and their parent/carer. Other areas 
would include knowledge of the progress made in all domains by the child, the support 
structures needed to be in place and support for parents. 
4.2 Integrated service provision 
Young people, particularly those under 16, who are identified as having a substance misuse 
problem, or are at risk of progression to problematic use, should be supported and 
encouraged to participate in substance awareness and education on facts about substances, 
motivational work and relapse prevention activities (NICE, 2007c). Substance misuse 
services should be adapted to the needs of the age and maturity of each young person to 
optimise participation and effectiveness. 
Early drug and alcohol initiation is seen as a high risk marker for future substance misuse. 
Quite often these young people will require intensive support. Specialist provision may need 
to be organised such as family support and interventions, educational assessment and return 
to appropriate educational settings, mental health services and intensive youth support 
services. All should be linked with young people’s substance misuse services by a care plan 
co-ordinated by a lead professional. 
Prior to any court appearance arrangements need to be put in place to ensure continuity of 
care should a young person be held in or sentenced to custody. This is crucial if young 
people are going to be helped to stay in treatment and continuity of care is to be 
established. All young people should be encouraged to take their substitute medication in 
the morning prior to the court appearance. Local protocols should be negotiated with the 
Youth Offending Team (YOT) for sharing of information and joint working arrangements 
to make any admission to custody as smooth as possible. 
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The period immediately following release from custody is a time of considerable 
vulnerability, especially to a relapse into drug and alcohol use with an increased risk of 
overdose and death. For those being discharged from custody on continuing prescribed 
medication a custodial establishment is likely to contact the community team so that an 
appointment is already arranged immediately following release, with careful handover of the 
prescription. Close working relationships between the custodial establishment, specialist 
community substance misuse service, the YOT and Resettlement and Aftercare Programme, 
where available, are central to securing good integrated care. 
Pre-release meetings should take place if possible between the custody team, the YOT 
worker, the specialist community substance misuse team and a CAMHS representative 
(where appropriate). There should be documented action points from the meetings (stored 
in clinical records) which are shared with all members of the team to ensure continuity and 
good practice in recording concerns and action. Parents should be invited to these meetings, 
with support provided for them too when their child is discharged. 
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�
Pharmacological approaches – key points 
•	� Pharmacological interventions for substance misuse can be used: 
–	� as an emergency response 
–	� to stabilise substance misuse 
–	� to detoxify from substances 
–	� to ameliorate withdrawal symptoms 
–	� to prevent relapse. 
•	� Pharmacological interventions for substance misuse in children and young people 
lack a strong evidence base, so extra care and caution should be used. 
•	� Pharmacological interventions should be: 
–	� preceded by an assessment 
–	� preceded by a drug screen 
–	� titrated against withdrawal symptoms 
–	� closely monitored and consumption supervised 
–	� part of a care plan, which includes psychosocial interventions. 
•	� Initiation of pharmacological management of substance misuse should be 
accompanied by support from the specialist substance misuse treatment service and 
from the young person’s parents/carers wherever possible. 
•	� A treatment regime should be chosen according to individual need and in 
consultation with the young person. A young person’s parents/carers should be 
involved whenever possible. 
•	� Clear procedures for responding to emergency overdoses should be in place. This 
should include access to naloxone and staff who can administer it and perform 
resuscitative procedures. 
•	� A period of stabilisation of at least 5 days is required for opioid prescribing, before 
reaching a decision on whether to adopt a maintenance or detoxification regime. 
•	� Longer-term stabilisation on opioids or detoxification from opioids, alcohol or 
benzodiazepines may be required. Additional ameliorative prescribing to control 
any withdrawal symptoms may also be required. 
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•	� In cases of poly-drug dependence concurrent detoxification is not	recommended. 
Alcohol detoxification should be completed first, followed by benzodiazepine 
detoxification and finally opioid detoxification. 
•	� Amelioration of withdrawal symptoms may include non-pharmacological 
interventions, such as adequate hydration in addition to any prescribed medication. 
•	� Pharmacological adjuncts to relapse prevention lack evidence in young people and 
are not recommended for routine use; they should be used only in conjunction with 
other support for the young person and with specialist advice. 
•	� Young people inducted into pharmacological treatment will require careful 
monitoring and supervised consumption of their medication. 
This chapter is concerned with the general principles of prescribing and choosing a 
prescribing regime, and more detailed prescribing protocols are described in later chapters. 
Pharmacological management of substance misuse does not constitute appropriate stand-
alone treatment. Substitution with pharmacological agents should be seen as a ‘structured 
doorway’ into other forms of psychosocial treatment (aimed at motivating the young person 
to become stable and/or abstinent, as well as at improvements in all domains of function). 
Pharmacological interventions should not be commenced, apart from emergency and urgent 
treatment, without a clear care plan that includes psychosocial interventions. 
Pharmacotherapy for substance misuse is directed at a number of specific areas, including: 
•	� treatment of overdose and other emergencies 
•	� substitute prescribing 
•	� detoxification 
•	� amelioration of or adjunct to amelioration of withdrawal symptoms 
•	� adjunct to relapse prevention. 
For young people, adverse effects directly related to drug and alcohol misuse are more often 
related to intoxication rather than dependence. Many young people may have a ‘binge drug/ 
alcohol history’ but this in itself would not denote a requirement for a pharmacological 
intervention. It is important that anxiety symptoms and/or an anxiety disorder are not 
confused with withdrawal symptoms and inappropriate treatment commenced. 
Regular, though non-daily, non-dependent injecting of opioids is not necessarily an 
indication for substitute medication. However, if there is chaotic misuse with unclear 
tolerance and with concern of overdose, a prescription might offer an opportunity to 
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stabilise behaviour and provide overdose protection. However, this form of pharmacological 
intervention should be undertaken only by a specialist. 
While there is substantial evidence for pharmacological interventions in adults this is not 
the case for children and young people. This is partly due to a lack of clinical trials for 
controlled drugs in minors, and partly to the relatively new initiative to provide 
pharmacological interventions for substance misuse to children and young people. For 
some drugs used in clinical management, there is little evidence on dose, on duration of 
treatment, or on adverse effects. Young people respond to drugs differently to adults, these 
responses being influenced by the physiological and psychological changes that occur in 
adolescence. In essence, children are not little adults, and it is essential that dose is carefully 
titrated against withdrawal symptoms to ensure that a young person does not overdose. 
Commencing a new prescribing regime can affect sleep and eating patterns and cause 
distress. It is recommended that young people and their parents/carers are forewarned of 
this and that there may be a need for additional food and hydration especially at night to 
help alleviate sleep problems which can be compounded by hunger and dehydration. 
Additional food and drink can be helpful until better sleep and eating patterns return 
and the risks of malnutrition, anorexia, hypothermia and hypoglycaemia are alleviated 
(Department of Health, 2006). 
5.1 Initiating prescribing 
The aim of prescribing a substitute drug for someone with physical dependence is to 
prevent withdrawal symptoms and further use of illicit drugs. A diagnosis of physical 
dependence should be made prior to initiation of medication; this is established by history, 
physical examination and corroborative evidence such as toxicology and information from 
other professionals. The history of substance misuse should show regular daily use of the 
specified substance over a prolonged period. 
5.1.1 What to prescribe 
Prior to the initiating of any prescribed treatment, practitioners must familiarise 
themselves with section 2.5 of this document ‘Prescribing responsibilities’, on pages 
13-15 of this document. It is usual to consider a long-acting drug, for example: 
•	� methadone and buprenorphine for opioid withdrawal 
•	� chlordiazepoxide or diazepam for alcohol withdrawal 
•	� diazepam for benzodiazepine withdrawal 
•	� lofexidine, which may be useful in treatment of withdrawal from opioids, 
particularly if there is mild physical dependence, unclear tolerance and a short 
history of use. 
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The doctor or non-medical prescriber should be aware of the licensing of drugs and its 
relevance to young people (see Sections 2.7 and 2.8). 
5.1.2 When to start 
Pharmacological management is required if the young person is physically dependent on 
drugs and/or alcohol. Young people should not experience untreated withdrawal symptoms. 
However, the doctor or non-medical prescriber should be sure that the symptoms are those 
of withdrawal and not exclusively those of a co-morbid disorder, or distress related to 
intoxication or post-binge or psychological difficulties. 
•	� The dose should be titrated against withdrawal symptoms. 
•	� The urine/oral fluid result should be positive for the drug(s) considered. 
•	� If the urine/oral fluid result is negative then clear and unambiguous withdrawal 
symptoms need to be observed and recorded. If there is any doubt a further 
period of observation is warranted prior to any prescription. If there is any 
continued doubt then more specialist advice is required. 
•	� Titrate the dose throughout the first day and then at least once a day for a further 
3 days – at least until steady state is achieved. 
•	� Doses of all drugs should be supervised. 
•	� Only oral preparations of the prescribed drugs should be dispensed. 
•	� There is no indication to prescribe injectables to young people. 
5.2 Settings of treatment 
Pharmacological management can be undertaken in a range of settings: specialist substance 
misuse treatment services, CAMHS, GP surgeries, and in-patient and residential services. 
Different arrangements for the titration and monitoring of pharmacological management 
may apply as a result of this, and GPs are strongly encouraged to work with specialist 
substance misuse treatment services to ensure that adequate monitoring and titration 
arrangements can be put in place. The minimum recommended is: 
Titrate	the	dose	throughout	the	first	day	and	then	at	least	once	a	day	for	a	 
further	three	days	–	at	least	until	steady	state	is	achieved. 
In community settings a supportive home environment is advantageous as this allows 
opportunities for support to be provided by parents/carers or another significant adult. 
Strong social support structures can help with compliance with medication and the 
provision of emotional support during induction and detoxification. Where a young person 
lives independently or in a non-supportive environment it would be beneficial to encourage 
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them to live temporarily with a relative or other supportive adult during significant changes 
to pharmacological management. Supporting adults, parents and carers will gain from 
meeting with the treatment provider and being familiarised with likely responses to the 
medication and alerted to possible problems and side effects. Parents/carers should be 
encouraged to attend overdose prevention and resuscitation training courses, or at least be 
given some information on these subjects by the service provider. This will improve the 
identification of and response to overdose should it occur. 
Induction onto, and detoxification from, prescribed medication and the cessation of alcohol 
and drug use are likely to cause anxiety. The treatment provider needs to offer as much key-
worker support as possible, and in addition 24-hour support from a parent or carer cannot 
be overvalued. Undertaking induction onto, or detoxification from, prescribed medication 
is not recommended for young people without suitable support mechanisms being in place. 
In some areas temporary specialist foster care places may be available where home support 
is lacking. 
For the more complex cases, day care settings with active parent/carer support or residential 
settings may be required. The most severe and complex cases, or those where home support 
systems cannot be found, may require in-patient or residential services in order to induct 
onto or detoxify from medication. It is not advisable to place young people in custodial or 
secure children’s homes merely to meet substance misuse treatment needs as these 
establishments have been developed primarily to meet other needs. 
5.3 adopting a regime 
Once a decision has been made to undertake pharmacological management, there are a 
range of regimes that can be used. These depend on the needs of the young person and 
on the goals of the treatment. 
5.3.1 emergency treatment 
For young people who are excessively sedated or unconscious, regardless of causation, 
emergency procedures should be put in place with immediate transfer to the local general 
hospital. 
Service providers are encouraged to have naloxone available for use in case of opioid 
overdose. All personnel should be aware of the location of this medication. Care should be 
taken with naloxone; it is short acting and may therefore need to be administered on several 
occasions to overcome the effects of overdose. Those young people who require this 
emergency procedure should be transferred urgently to the local general hospital, with 
naloxone available en route. It is recommended that staff trained in the administration of 
naloxone and resuscitative procedures are available during the process of titration onto 
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medication. There should be a protocol on the use of naloxone that is known by staff and 
capable of implementation and audit. The protocol for the particular route of use will 
depend on the setting and availability of trained staff in the institution. Protocols should be 
in place and agreed with all personnel. 
If a practitioner or any person believes a child or young person to be suffering from possible 
alcohol poisoning, any decline in consciousness should trigger a transfer to general hospital, 
to ensure both treatment and review of any poly-substance use. Staff trained in resuscitative 
procedures should be available on all shifts. 
5.3.2 Substitute prescribing 
The main purposes of substitute prescribing are: 
•	� to provide treatment for withdrawal symptoms via induction onto substitute 
medication upon assessment of dependence on opioids, alcohol or 
benzodiazepines 
•	� to keep side effects to a minimum and reduce the need for further illicit drugs 
•	� to continue an established prescription from another provider, including those 
in custodial settings. There is good evidence that engagement with community 
specialist drug programmes following release from custody may have beneficial 
effects on health and on offending behaviour (Mattick et al, 2002) 
•	� to reduce the risk of fatal drug overdose especially upon release from custody. 
The prescribing of substitute medication should be commenced with a short period of 
stabilisation, followed by a planned detoxification regime or maintenance for opioid 
dependence. Detoxification or maintenance decisions should be based on clinical need 
and follow a comprehensive assessment. 
The term ‘stabilisation’ means the moderating and control of withdrawal symptoms during 
a given period of time of no less than 5 days. Stabilisation is achieved through a process 
of dose induction – the gradual introduction of medication titrated in response to 
withdrawal symptoms. 
A short stabilisation period permits time for input from professionals from other services, 
including custodial establishments, to inform decisions for the care plan. Dose reduction 
regimes or maintenance should be tailored to the individual, shaped by a realistic appraisal 
of treatment goals between the young person, their parents/carers and the clinical team. 
A young person expecting to commence a custodial sentence in the near future would 
benefit from continuity of care between the community and custodial settings. The YOT 
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can act as a contact between the services and can provide advice on the most likely custodial 
establishment that the young person may be sent to. Discussions can then be entered into 
with the custodial establishment regarding continuity of care options in this site. 
Increasingly custodial establishments are encouraged to provide a range of pharmacological 
interventions for substance misuse and continuity of care with community services. As such 
detoxification prior to transfer to custody may not be required as the custodial 
establishment may be willing to continue a maintenance regime, where it is in the best 
interests of the young person. However, each custodial establishment is different and as 
such contact should be made with each custodial facility and plans for individual care 
developed rather than making assumptions about the type of interventions available. 
Where there is a high likelihood of a young person returning to injecting opioid use upon 
release from custody, maintenance of the prescription while in custody may be provided 
both on the grounds of engagement in services and stabilisation of all domains of 
functioning, and on the grounds of post-release overdose prevention. Random clinical 
testing for illicit drug usage should form a part of any maintenance programme. It is 
imperative that community settings are involved in the continuation of the care plan and 
have contributed to its formation prior to the discharge. 
Maintenance with opioids provided alongside psychosocial interventions can enable users 
to achieve stability, reduce drug use and other illegal behaviours and demonstrate 
improvements in many domains of functioning. Maintenance as a goal remains 
controversial in young people with little evidence on outcome to guide the clinician. 
Most clinicians would suggest that maintenance with no time-frame of reduction for young 
people, especially those under 16 with a short opioid history and few other difficulties, 
would not be recommended. 
However, maintenance may be a viable option provided that there is a regular and frequent 
review of the care plan. This option of maintenance in the short term might be particularly 
important to a young person with a history of chaotic use who has not previously engaged 
in treatment or who has not stabilised in the community environment. It is, however, 
somewhat different for the older adolescent (17–18 years and onwards), who might have 
a long history of opioid use. In this case maintenance over a longer period should be 
considered with goals reviewed regularly. 
It may be appropriate to set up a formal detoxification regime, agreed with the young 
person and their parents/carers. Decisions on the regime should be based on individual 
needs. The NICE (2007c) guideline on opioid detoxification recommends regimes that can 
last up to 12 weeks. A period of stabilisation followed by detoxification may be appropriate 
for some young people in line with their care plan and review. 
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In some instances young people and their parents/carers may wish to reduce or stop 
substitution drug therapy. This option should be offered and discussed with the family and 
young person. The opportunity to be drug-free may be particularly important, but should 
be balanced against the potential risks of such a strategy. All young people and their parents/ 
carers should be warned about the increased risk of overdose, both from reduction of 
tolerance and relapse into poly-drug use. It is essential that those who have been on 
prescribed opioid replacement with slow reduction or had detoxification should be engaged 
by appropriate psychosocial services and support. Those who are recently abstinent have a 
significantly high risk of overdose and relapse into drug use. 
5.3.3 Detoxification 
Detoxification refers to the process by which the effects of drugs are eliminated from 
dependent users in a safe and effective manner, so that withdrawal symptoms are 
eliminated. This process may be carried out by using the same drug, or another which has 
a similar effect, in decreasing doses. It can also be assisted by the prescription of adjunctive 
medication to reduce withdrawal symptoms (NICE, 2007c). 
Opioids 
There are several pharmacological options for opioid detoxification, including non-opioid 
based medication. Opioid detoxification will depend on: 
•	� the young person’s wishes and needs (and parental considerations) 
•	� the setting of detoxification 
•	� the severity of physical dependence and history of dependence 
•	� other complex needs, e.g. mental health and pending custodial sentence. 
For many young people, especially those under 16 years and with a short history of mild 
opioid physical dependence, detoxification is considered appropriate. For some, particularly 
those older adolescents with more complex problems and a longer history of opioid and 
poly-drug dependence, clinicians may wish to stabilise for a period of up to a few months, 
using methadone or buprenorphine with the objective of stabilising other aspects of life, 
and improving functioning with parents/carers and peers. Once some stabilisation is 
achieved, the methadone or buprenorphine can be gradually reduced. 
When determining the dose, duration and regimen of opioid detoxification, healthcare 
professionals should, in discussion with the young person and their parents/carers, when 
appropriate, take into account in accordance with NICE (2007c) the: 
•	� severity of the dependence 
•	� stability of the young person (e.g. other substance dependence and mental health 
issues) 
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•	� context and setting of the detoxification 
•	� pharmacology of the chosen detoxification medication and any adjunctive 
medication 
•	� possibility of a custodial sentence or move to secure accommodation 
•	� risks of self-harm, overdose or death 
•	� practical difficulties in assessing dependence and the associated risk of opioid 
toxicity early in treatment. 
NICE (2007c) states that the duration of opioid detoxification should normally be up to 
4 weeks in an in-patient or residential setting and up to 12 weeks in a community setting. 
Following successful opioid detoxification, and irrespective of the setting in which it is 
delivered, continued treatment should be offered. This should take the form of 
interventions designed to provide support and monitoring to maintain abstinence. 
This should normally be for a period of at least 6 months (NICE, 2007c). 
Alcohol 
Though alcohol dependence is not common in young people, one should be alert to the 
possibility of dependence in those who are drinking excessively or who binge drink. Alcohol 
misuse is commonly associated with other illicit and prescribed/over-the-counter drug use in 
younger people. For all those young people who report alcohol and drug use, a careful and 
comprehensive assessment of alcohol use should be made. A minority of young people may 
be dependent on alcohol, making them at risk of more serious withdrawal complications, 
such as delirium tremens and seizures. These two conditions are potentially fatal, so it is 
essential that all young people are thoroughly assessed and receive detoxification when 
required. If they are not dependent, it is important to address alcohol misuse using brief 
interventions, family interventions and individual motivational therapy (Heather, Raistrick 
and Godfrey, 2006 and NTA, 2008b). 
Benzodiazepines 
Benzodiazepines are misused by young people, often alone or together with other illicit drug 
misuse, including for symptomatic relief following stimulant use, or to boost the effect of 
methadone or other opioids. A further group may be prescribed benzodiazepines for anxiety 
states or sleep difficulties. Cessation of benzodiazepines can lead to a recognised withdrawal 
state, where there is risk of seizures. Other withdrawal symptoms include anxiety, insomnia, 
nausea, headaches and tremor. In the most extreme cases the young person may experience 
psychotic agitation, depersonalisation or delirium. A slow reducing approach should be 
taken to detoxification. 
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Poly-substance	dependence 
In cases of current dependence on a combination of alcohol, opioids and benzodiazepines, 
more than one reduction regime may be required. Prescribing should proceed with 
additional caution due to the interaction of these drugs. In the context of opioids and 
physical dependence on alcohol, pharmacological management of both dependences should 
commence at the same time, and the alcohol detoxification regime should then be managed 
with the opioid dependence stabilised (generally using buprenorphine or methadone) until 
the alcohol detoxification is complete (NICE, 2007c). Such management may assist in 
reducing the risk of impulsive self-harming behaviour. 
For dual alcohol and benzodiazepine dependence, clinicians may wish to combine the 
regimes using an increased level of chlordiazepoxide for the first seven days to cover both 
alcohol and benzodiazepine withdrawal regimes. Following this the chlordiazepoxide can 
be converted to an equivalent once daily dose of diazepam to manage the benzodiazepine 
dependence; this should be a planned gradual reduction which is regularly reviewed. 
5.3.4 amelioration of withdrawal symptoms 
Withdrawal from drugs and alcohol may cause distressing symptoms that may require 
additional supportive management and pharmacological responses at times. These 
ameliorating regimes are not in themselves appropriate to use for detoxification alone but 
are adjuncts to ease distress. Adjunctive treatment of symptoms during withdrawal should 
be regarded as part of active clinical management with due care and risks considered. 
NICE (2007c) suggests caution when prescribing adjunctive medication: 
•	� Only use when clinically indicated, such as agitation, nausea, insomnia, pain or 
diarrhoea. 
•	� Use the minimum effective dosage and number of drugs needed to manage 
symptoms. 
•	� Be alert to risks of adjunctive medications, as well as interactions between them 
and opioid agonists. 
Patients should be monitored frequently during the induction/stabilisation phase to ensure 
that symptoms are controlled – deaths have occurred in the past as a consequence of 
uncontrolled vomiting and dehydration during detoxification in custody. Vomiting and 
diarrhoea should therefore be managed by effective hydration and if necessary prescribing 
of carefully monitored anti-emetic and anti-diarrhoeal medication. In-patient care is 
recommended if symptoms are not adequately controlled within 24 hours or where there 
is a clear indication of significant medical complications developing. The Department of 
Health (2007) concludes that there is no systematic evidence that any of these symptomatic 
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medicines work to improve the outcome of opioid treatment though they may be useful to 
the clinician in situations where for safety reasons initial dose titration should be undertaken 
with extreme caution. Particular care is needed concerning the risk of poly-pharmacy and 
ensuring that appropriate supervision and support are in place in each case. 
The following medications are suggested for adjunctive therapy, where required 
(Department of Health, 2007): 
• diarrhoea – loperamide 
• nausea and vomiting – metoclopramide, cyclizine or prochlorperazine 
• stomach cramps – mebeverine 
• muscular pains – paracetamol or non-steroidal anti-inflammatory drugs. 
Symptoms such as anorexia, hypothermia and hypoglycaemia are common problems during 
the early stages of drug withdrawal. Young people should be encouraged to increase their 
intake of food, naturally sweetened drinks and other fluids during this phase. Additional 
food and fluids may help during the recovery phase of withdrawal, when the appetite 
returns and sleep problems occur, to ensure that these problems are not further aggravated 
by hunger or thirst. 
Insomnia is a common symptom of stimulant, opioid, alcohol and benzodiazepine 
withdrawal. This may be disabling, causing significant anxiety and distress, and should be 
regarded as a potential risk factor for self-harm and suicide. It is recommended that a range 
of non-pharmacological interventions should be available to young people experiencing 
insomnia, such as support and access to sleep advice. 
Prescription of hypnotics should be considered very carefully. If insomnia becomes 
particularly problematic, a short-acting hypnotic may be prescribed for a limited period 
(a few days) and reviewed according to patient response. This action should be reserved for 
those who have not responded to other sleep aids and who have completed detoxification or 
stabilisation of medication and yet have not been able to recover their sleep patterns. These 
hypnotic drugs are in themselves dependence forming and liable to misuse. The possibility 
of interaction between methadone and hypnotics should also be considered when deciding 
on treatment. Continued insomnia should be assessed; this may be related to tranquilliser 
withdrawal, unrecognised depression or other physical problems. 
Where insomnia has not been resolved with non-pharmacological approaches and where it 
is causing daytime fatigue and/or distress, a short course of a short-acting benzodiazepine 
(loprazolam, lorazepam, lormetazepam and temazepam) or Z-drug (zaleplon, zolpidem or 
zopiclone) may be considered (Department of Health, 2007 and NICE, 2004). These short 
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courses should last no more than a few days as dependence can develop. In severe cases 
advice should be sought from an addiction or CAMHS psychiatrist. 
It is not appropriate to prescribe anti-depressant drugs such as mirtazepine just to use its 
sedative properties. The use of anti-depressants in young people needs to be very carefully 
managed and they should not be used unless in conjunction with child and adolescent 
psychiatric advice and in accordance with NICE (2005) advice. 
5.3.5 adjunct to relapse prevention 
Some drugs are useful in helping to maintain abstinence by blocking the effects of opioids 
or alcohol. However, they are not without complications. They have little evidence base 
for use in young people and should be carefully considered before prescribing is initiated. 
In general, because of the lack of evidence in young people, the use of this medication is not 
recommended. If it is considered, the young person should be highly motivated, aware of 
the potential adverse effects and able to access a wider programme of care from community 
specialist teams (and family members/carers where possible) who have agreed to support the 
young person (NICE, 2007b). Supervised consumption of this medication is recommended. 
It may be considered for older adolescents but should be part of a comprehensive care plan, 
supervised and regularly reviewed. 
5.4 monitoring the induction process 
It is essential that those who are undergoing pharmacological interventions are monitored 
closely. Young people should be seen by the specialist substance misuse treatment team 
several times on the first day during the initial titration and then at least once daily for a 
further three days or until a stable dose is reached. This is to observe for problems either as 
a consequence of withdrawal symptoms, such as fitting, vomiting and distress, or for side 
effects of medication, such as a sudden reduction in blood pressure, drowsiness and excess 
sedation. Parents/carers wherever possible should be encouraged to help with this 
monitoring and given clear information about signs to look for and who to contact 
if they have concerns. 
Recorded observation should be ongoing throughout the first phase of pharmacological 
management, and ideally should last for the whole of the stabilisation or detoxification 
period. This should include frequent clinical reviews, usually co-ordinated by a nurse. 
Reviews should consist of general observation, gait, and physical determinants such as blood 
pressure, pulse, temperature and signs of agitation or sedation. These symptoms could 
reflect inadequate or excessive medication or poor tolerance during induction phases. 
Protocols should be available on observational methods such as general demeanour, blood 
pressure, pulse, temperature and urine/oral fluid testing and these should be recorded. 
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Breathalysers can be used to ensure that no illicit alcohol use is continuing during an 
alcohol detoxification. 
Any signs of drowsiness, slurred speech, droopy eyelids, or lowering of blood pressure, or 
any security information received that might indicate illicit drug or alcohol use or excess 
dose of prescribed medications should be acted upon (see Section 5.4). 
Withdrawal scales in relation to drugs and alcohol can be useful, and they allow careful and 
routine enquiry with the young person about their symptoms. Symptoms and the response 
of the team to the symptoms should be recorded when these scales are used. However, while 
they are useful, should never take the place of clinical assessment and regular review. 
It is necessary to assess routinely and frequently the mental state of the young person, 
paying particular attention to the increased likelihood of self-harming as withdrawal 
proceeds. It is imperative that the drug and alcohol dependence is adequately and 
appropriately managed, so as to reduce incidence of self-harming behaviour and suicide. 
Use of rating/monitoring scales for mental state would again be useful in the day-to-day 
observation and monitoring of these young people. 
Ongoing reviews by the same team should occur where any extended prescribing regimes 
are in place, to ensure that the original plan is adhered to, or adjusted if circumstances 
change. 
5.5 Supervised consumption of medications 
Department of Health (2007) and NICE (2007a) recommend that all new prescriptions for 
the management of substance misuse are given under supervised consumption conditions 
for approximately three months, tailored to individual need. 
Community pharmacists will be involved in the dispensing of supervised medication. 
Initially there should be discussions with the service provider on the identity of the young 
person and if appropriate with a parent/carer. It is good practice to liaise frequently with 
the pharmacist. 
In the event of suspicion of other drug use, intoxication or days where medication has not 
been dispensed, the specialist service should be contacted prior to medication being 
dispensed. Specialist services may need to reassess the young person. If there is sedation 
which continues despite withholding drugs, an urgent response and possible in-patient 
admission may be required. 
Parents/carers can be encouraged to supervise the consumption of take-home medication 
during weekends and public holidays when professional supervision is not available. This 
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is appropriate where the parent/carer has received advice by a pharmacist or the service 
provider. Induction and detoxification regimes are best not started when professional 
supervision is not available (e.g. at the weekend). 
Buprenorphine 
Particular care needs to be taken in the supervision of buprenorphine as it will become 
inactive if swallowed. It should be allowed to dissolve slowly under the tongue and such 
supervision can take at least 10 minutes. Sometimes local protocols are available with the 
pharmacist to crush the tablets, allowing faster supervision. 
An advantage of the longer supervision period is the opportunity to engage with the young 
person, increasing informal discussion during the observation period. 
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6. opioid prescribing protocols
�
opioid prescribing protocols – key points 
•	� The use of methadone, buprenorphine and lofexidine is recommended. 
•	� Dosage for a young person is likely to be relatively lower than for adults though 
there is no evidence base to guide this. 
•	� Methadone or buprenorphine should not be prescribed in the absence of positive 
drug testing and/or observable withdrawal symptoms. Non-opioid medication, such 
as lofexidine, should be used as an alternative if prescribing is deemed necessary and 
tolerance is unclear. 
•	� A period of at least 5 days’ stabilisation should be achieved prior to detoxification 
regardless of the medication used, unless lofexidine is used for safety reasons because 
of concerns about dependence and tolerance. 
•	� Stabilisation on a dose may be appropriate to manage an individual’s needs. 
•	� In induction always titrate doses to withdrawal symptoms and observe for 
over-sedation. 
•	� Detoxification should be a gradual process; consider up to 12 weeks, and in some 
cases longer tapering of dose may be required. 
•	� For all detoxifications adjunctive medical and non-medical treatments may be 
required, though evidence for symptomatic prescribing is poor. 
•	� Arrangements should be put in place to help to ensure continuity of care from 
custodial to community settings. 
•	� Naltrexone should only be used in young people where there is strong community 
support from both substance misuse specialists and family/carers. Young people should 
also be highly motivated and understand the full implications of the medication. 
This chapter guides the practitioner in the management of opioid dependence. In line with 
NICE (2007d) guidance in this document the term ‘opioid’ will be used to refer to the 
whole group of natural, semi-synthetic and synthetic compounds that act on opioid 
receptors. It includes guidance on induction, stabilisation and detoxification regimes using 
methadone, buprenorphine and lofexidine. All of these drugs are effective in treatment. 
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Maintenance is generally not a goal in adolescents though a small but perhaps significant 
minority of young opioid users may benefit from short-term maintenance followed by a 
slow reduction. This could last for some months depending on the severity of dependence, 
social support structures and ability to safely reduce prescribed medication without relapse. 
As a caveat to all pharmacological approaches, they should be administered within an 
overall comprehensive care plan. 
Before commencing pharmacological management for opioid use physical dependence 
should be established. The full range of indicators of dependence should be considered 
in making prescribing decisions. 
High-quality reviews on the three main methods of detoxification from opioids are available 
(NICE, 2007a and 2007d and Department of Health, 2007). Although these relate to 
adults (those aged from 16) there was minimal evidence available to be included in these 
reviews on detoxification from opioids specifically from populations of young people (those 
under 18 years). The methods of opioid detoxification are: 
• tapering methadone 
• tapering buprenorphine 
• use of lofexidine. 
6.1 medication for the treatment of opioid dependence 
Prior to the initiating of any prescribed treatment, practitioners must familiarise 
themselves with section 2.5 of this document ‘Prescribing responsibilities’, on pages 
13-15 of this document. Methadone and buprenorphine are both approved for the 
treatment and prevention of withdrawals from opioids, though licensing arrangements differ 
in young people. The choice of methadone or buprenorphine depends on a number of 
factors, including: 
• level of opioid use 
• safety, e.g. risk of diversion and overdose 
• concomitant dependence on other drugs such as benzodiazepines and alcohol 
• severity of dependence 
• patient preference 
• history of use of either or both drug(s) in treatment 
• retention and treatment compliance 
• prescribers’ experience 
• context and setting of treatment. 
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The Department of Health (2007) notes that evidence suggests that methadone is more 
likely to retain people in treatment, though the evidence for the relative effectiveness of 
methadone and buprenorphine in preventing illicit drug use is mixed. NICE (2007a: p4) 
recommends: 
“If both drugs are equally suitable, methadone should be prescribed as the first choice.” 
In order to make decisions about which medication is most suitable in the treatment of 
opioid dependence, it is important to understand the differences between them, and how 
they compare to heroin. 
The timing of the onset of withdrawal symptoms will depend on the opioid that an 
individual has developed physical dependence to; this is due to the half-life of the opioid. 
The shorter the half-life the quicker withdrawal symptoms will be observed and the longer 
they are likely to last, as the opioid will take longer to completely stop its effect. The half-
life of a drug is the name given to the time it takes for blood levels of a drug to drop to 
50% of the peak concentration. 
Heroin fits opioid receptors almost perfectly and stimulates them strongly. It also inhibits 
the release of noradrenalin, which causes the body to produce more noradrenalin. 
Continued use of heroin inhibits the release of this noradrenalin. On cessation of heroin 
use, noradrenalin is released in excess of normal levels, causing many of the unpleasant 
symptoms associated with heroin withdrawal (Preston, 2004). The half-life of heroin is 
around 3 hours. 
Methadone binds well to opioid receptors and stimulates them in a way that is similar to 
heroin. It has a less intense but longer lasting effect. It has the same effect on noradrenalin 
production as heroin (Preston, 2004). The half-life of methadone depends on whether it is 
a first dose or part of daily consumption. The half-life of a single first dose is around 15 
hours; the half-life of regular methadone consumption is around 25 hours (Preston, 1996). 
It is generally advised that methadone following a stabilisation period of 5 days should be 
slowly reduced in a linear fashion. The reduction should last at least 14 days, perhaps longer 
if withdrawing from prescribed methadone or buprenorphine rather than illicit heroin. 
It would be likely to be longer in those with more severe and longer dependence. Short 
detoxification should be recommended only for those with short histories of dependence 
who have titrated to low levels of methadone and wish to detoxify quickly and have given 
their full consent to do so. Evidence suggests that a slower detoxification from methadone is 
associated with improved completion rates. The duration of opioids detoxification should: 
“... normally be up to 4 weeks in an inpatient/residential setting and up to 12 weeks in a 
community setting.” (NICE, 2007d: p15). 
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The detoxification plan should be reviewed at least weekly, more frequently if the 
detoxification is rapid, with review of the overall care plan occurring frequently during the 
detoxification process. Withdrawal symptoms can present later in the detoxification period 
rather than in the early phase of the process. Equally for those with maintenance needs, the 
care plan should be reviewed frequently. 
Methadone is considered useful as it: 
•	� is evidence based (in adults) 
•	� is relatively straightforward to titrate against withdrawal symptoms 
•	� can be dispensed once daily (following stabilisation) and is easy to supervise 
•	� can be used in pregnancy (see Section 8.3). 
Buprenorphine binds very well to opioid receptors, so well that if any methadone or heroin 
is still attached to the receptors it will be displaced, which will precipitate withdrawal 
symptoms and stop heroin and methadone having their usual effects. Buprenorphine does 
not stimulate the opioid receptors strongly. It has the same effect on noradrenalin 
production as heroin (Preston, 2004). Buprenorphine’s half-life is between 20 and 37 hours 
(Royal College of General Practitioners, 2004). 
Buprenorphine is considered to be less dangerous in overdose than methadone and is useful 
for both maintenance and detoxification, anecdotal reports of ‘clearer heads’ are reported 
and with maintenance doses use of illicit opioids is reduced. Disadvantages include the 
length of time required for supervised consumption of sublingual tablets, the diversion 
potential, misuse of the drug, precipitated withdrawal and expense. 
Buprenorphine should not normally be used in those who: 
•	� have been taking or have been prescribed methadone in quantities greater than 
20–30 mg per day 
•	� require analgesia, possibly opioid based 
•	� have abnormal liver function tests 
•	� are pregnant. 
Caution should be used in prescribing buprenorphine to those with benzodiazepine 
dependence due to the increased risk of fatal overdoses. 
The risk of precipitated withdrawal is the main problem with induction. 
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Achieving a stabilisation dose, one that has no withdrawal symptoms and seeks to avoid any 
craving, may take 1–2 weeks. The dose for maintenance in adults is regarded as between 
8 and 32 mg but the most common effective maintenance dose is between 12 and 16 mg 
(adults) though some need higher doses. Young people may require a lower dose than adults 
to achieve stabilisation, for example around 8 mg of buprenorphine. This is satisfactory 
provided that it is decided on an individual basis and there are no cravings or withdrawal 
symptoms. 
Suboxone is a new formulation of buprenorphine which is now available; it includes the 
opioid antagonist naloxone in a combined sublingual tablet, in a ratio of 4:1 of 
buprenorphine:naloxone. 
This new form is used at the same dose, that is, 8 mg of buprenorphine (Subutex) is the 
same as 8 mg of the new combination of buprenorphine and naloxone (Suboxone). The 
combination is expected to provide the same therapeutic effect while preventing or reducing 
the liability for misuse. This is based on the rationale that when taken sublingually the 
naloxone has a low bioavailability and does not diminish the therapeutic effect. However, 
when injected the naloxone has a high bioavailability and may precipitate opioid 
withdrawal, which is therefore likely to discourage injection of the drug. Misuse 
intra-nasally appears to have variable effects. 
Lofexidine does not affect the opioid receptors and so does not have any heroin-like effects. 
Lofexidine reduces withdrawal symptoms by preventing too much noradrenalin production, 
the cause of many, but not all, physical withdrawal symptoms (Preston, 2004). 
For those young people who do not want to use methadone or buprenorphine and have a 
mild history of dependence with relatively low levels of illicit use, lofexidine could be 
considered as a first choice for detoxification. This may be the option of choice for young 
people with presumed low or unknown tolerance to opioids. 
Lofexidine may be considered for those: 
•	� “who have made an informed and clinically appropriate decision not to use 
methadone or buprenorphine for detoxification 
•	� who have made an informed and clinically appropriate decision to detoxify within a 
short time period 
•	� with mild or uncertain dependence (including young people).” 
(NICE, 2007d: p14) 
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Lofexidine could be initiated at the start of the treatment process or it could be commenced 
following a 5 day stabilisation period of methadone or buprenorphine, provided that a high 
stabilisation dose is not required, in which case lofexidine may be used at the end of a 
tapering opioid detoxification. 
Reported side effects include dry mouth and mild drowsiness, though if the person is 
drowsy, one should be alert for other concomitant drug use. Lofexidine may cause 
bradycardia or hypotension (lowered blood pressure) in some people. Blood pressure and 
pulse rates should be checked prior to initiation, and then prior to the administration of 
each dose for at least the first 72 hours of the detoxification regime and for longer if there 
are problems. The safety of this drug is not established for those young women who are 
pregnant or breastfeeding. 
6.1.1 Poly-drug management 
In cases of current dependence	on	any	combination	of	alcohol,	opioids	and	 
benzodiazepine, more than one reduction regime may be required. Prescribing should 
proceed with additional caution due to the interaction of these drugs. In the context of 
opioid and alcohol physical dependence a more graduated individual approach will be 
necessary; the opioid regime should remain stable while the alcohol detoxification is taking 
place. Such management may assist in reducing the risk of impulsive self-harming 
behaviour. For the management of both alcohol and benzodiazepine dependence, clinicians 
may wish to combine the regimes using an increased level of chlordiazepoxide for the first 
seven days to cover both alcohol and benzodiazepine withdrawal regimes. Following this the 
chlordiazepoxide should be converted to an equivalent level of diazepam with a once daily 
dosing regime. A clear gradual reduction regime of the diazepam should be instigated; the 
speed of this reduction will depend on the assessed needs of the young person and should 
be frequently reviewed. 
Naltrexone	may be prescribed following detoxification for those who require assistance to 
sustain abstinence from opioids. However, the evidence base for the clear recommendation 
of naltrexone to prevent relapse to opioid dependence is currently weak (British Association 
for Psychopharmacology, 2004) and care should be exercised particularly with the younger 
child/young person. 
NICE (2007b) recommended that naltrexone should: 
• be considered as a treatment option in detoxified, formerly opioid dependent 
people who are highly motivated to remain in an abstinence programme 
• only be administered under adequate supervision 
• always be accompanied by full information on potential adverse effects 
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•	� be part of a programme of supportive care 
•	� be under regular review with discontinuation if there is evidence of misuse. 
Young people who are being considered for this therapy should be given full information 
prior to commencement, in leaflet form as well as verbally. Parents/carers should be 
involved wherever possible. Poor compliance or cessation of naltrexone significantly 
increases the risk of overdose and subsequent fatality if opioids are used following the 
loss of tolerance to opioids. 
Young people should be cautioned against any attempt to overcome the blocking effect 
of naltrexone by the use of increasing amounts of heroin. All young people commencing 
naltrexone treatment should be issued with a medical alert card, with advice on analgesic 
requirements. The patient’s GP should be informed of this treatment. 
6.2 Deciding if pharmacology is required for opioid use 
Methadone or buprenorphine should not be prescribed to a patient who has produced 
a negative opioid urine/oral fluid test unless they exhibit clear objective signs of opioid 
withdrawal or evidence of recent use by way of a confirmed and supervised dispensed 
prescription. 
In the absence of positive urine/oral fluid analysis or objective withdrawal symptoms it is 
advisable to use a non-opioid medication such as lofexidine, if prescribing is required, at 
least until objective withdrawal symptoms emerge. Negative urine/oral fluid analysis can 
sometimes occur in those who are dependent because they have been unable to obtain 
supplies of opioids for several days, perhaps due to time held in police cells. In these cases 
objective withdrawal symptoms will be present and can be used to help to confirm 
dependence. It should be borne in mind that the absence of opioids for a number of 
days will reduce tolerance levels, and great care will be needed on dose induction to 
avoid overdose. 
Induction of a young person onto an opioid to avoid and ameliorate withdrawal symptoms 
should be carefully conducted. 
The following factors can help to decide if pharmacology is required: 
•	� a careful assessment of past history – to include quantity, frequency, when last 
used and route of use of opioids, but also benzodiazepines, alcohol and other 
illicit drugs 
•	� presence of withdrawal symptoms 
•	� an opioid positive urine/oral fluid test 
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•	� physical objective signs of use, e.g. injecting sites (although not all those who are 
dependent will inject) 
•	� corroboration of history and treatment history with other practitioners. 
Objective and subjective signs of opioid withdrawal are described in Table 1. Due to the 
different half-life periods of different opioids withdrawal symptoms present at different 
times. Untreated heroin dependence shows early withdrawal symptoms within 8 hours with 
peak symptoms at 36–72 hours. Methadone and buprenorphine withdrawal occurs later 
with longer lasting symptoms before subsiding. 
table 1: Signs of opioid withdrawal (Department of Health, 2007) 
objective signs of opioid withdrawal Subjective signs of opioid withdrawal 
Yawning 
Coughing 
Sneezing 
Runny	nose 
Lachrymation	(watery	eyes) 
Raised	blood	pressure 
Increased	pulse 
Dilated	pupils 
Cool,	clammy	skin 
Diarrhoea 
Nausea 
Fine	muscle	tremor 
Restlessness 
Irritability 
Anxiety 
(The	signs	listed	above	may	also	be	useful	 
objective	signs) 
Sleep	disorders 
Depression 
Drug	craving 
Abdominal	cramps 
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Opioid	prescribing	protocols 
Initial doses should be titrated to relieve withdrawal symptoms, without inducing 
intoxication. The symptoms and signs of opioid overdose are: 
•	� nausea and vomiting 
•	� pin-point pupils 
•	� drowsiness 
•	� cold, clammy, blue-ish skin 
•	� reduced heart rate 
•	� reduced systolic blood pressure 
•	� reduced body temperature 
•	� breathlessness
•	� respiratory depression 
•	� cyanosis – convulsions (due to lack of oxygen) 
• death. 
(Preston, 1996) 
The following factors should be considered when deciding on initial dose and beginning the 
induction process: 
•	� age, weight, body mass and physical development 
•	� be aware of possible drug interactions (see Department of Health, 2007) 
• tolerance and dependence
�
• other poly-drug use
�
•	� accumulated toxicity particularly with methadone. 
To ensure safe prescribing the following procedures should be in place: 
•	� Titration and frequent monitoring by specialist staff is undertaken during 
induction and detoxification. 
•	� In the event of any sign of drowsiness – withhold the due dose of methadone and 
any other sedating medication that could affect respiratory function pending 
reassessment. In the event of drowsiness, care should be taken that the young 
person has not taken other non-prescribed medication and/or alcohol. Careful 
observation is important. Dose should be withheld until the specialist treatment 
service is clear about the cause of the drowsiness and this has abated. Where 
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sedation is sustained, the young person may need transfer to a general hospital 
setting. 
•	� A defined period of at least daily recorded observations should be put in place, 
until steady state is reached. 
6.3 methadone induction regime 
Prior to the initiating of any prescribed treatment, practitioners must familiarise 
themselves with section 2.5 of this document ‘Prescribing responsibilities’, on pages 
13-15 of this document. To ensure safety, methadone should be commenced through a 
process of induction. Methadone should normally be prescribed as a 1 mg in 1 ml oral 
solution. It is important to start on a low dose, observe for withdrawals and increase 
accordingly, as there is a lack of evidence for methadone treatment in young people. 
Inappropriate dosing can result in overdose related to cumulative toxicity in the first few 
days. The initial dose will be in the range of 5–10 mg. This is lower than that advised in 
adults, due to the shorter history and often uncertain tolerance of young people. The 
observation period for expected response for a single dose is up to at least 4 hours because 
of the long and variable half-life of methadone. Any requirement for supplemental doses 
should be assessed by an experienced medical practitioner. In general, caution with frequent 
and rapid induction is advised in high-risk young people, or those with uncertain tolerance. 
Greater caution should be taken in the custodial setting, if the young person cannot be well 
observed. Steady state plasma levels are generally expected within about 5 days, and 
therefore close observation is necessary until stabilisation is achieved. 
Great care must be taken in estimating dose levels that approximate with illicit heroin, 
as the purity and consequently the strength of street heroin fluctuates markedly. 
An individual can only approximate how much they have used and this may be inaccurate. 
Induction	regime: 
•	� Full explanation of methadone, its toxicity and induction regime should be given 
to the patient and to their parents/carers. 
•	� Methadone is commenced at least 8 hours after the last heroin dose provided that 
there is objective evidence of withdrawal symptoms. 
•	� Urine/oral fluid test should be positive for opioids. 
•	� A starting dose of 5–10 mg of methadone is administered – this should be 
supervised. 
•	� Withdrawal severity scales can be useful in assisting with withdrawal monitoring 
and in conjunction with intoxication monitoring, though they should not take 
the place of clinical observation. 
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• Further methadone is titrated against withdrawal symptoms and intoxication signs. 
table 2: methadone induction regime 
Suggested titration doses 
Day	1	 10–25	mg	methadone 
Day	2	 Methadone	15	mg	BD 
Day	3	 As	day	2	 
Day	4	 Up	to	40	mg	depending	on	response	to	day	3	dose	 
Day	5	 30–40	mg	mane	–	can	be	given	at	this	time	on	a	daily	basis 
Assuming that titration starts in the morning and withdrawal symptoms have been 
observed, 5–10 mg of methadone may be given in response to objective withdrawal signs. 
Further doses may be needed during the day but rarely is more than 30 mg required unless 
in an in-patient setting where 24-hour observation is achievable. Additional doses should 
not be given within a 4–6-hour window because of the time required to achieve blood peak 
levels and due to the long half-life of the drug. 
The protocol above notes a methadone titration up to 40 mg. There may need to be further 
administration of methadone on days 2 and 3, depending on the severity of dependence, 
observable withdrawal symptoms and the dose received on the previous day(s). However, 
increases of dose should not generally be in excess of a further 10 mg, increases need careful 
monitoring and the total dose should not be higher than 30 mg above the first day dose in 
the first week (Department of Health, 2007). If higher doses are required, then specialist 
advice should be sought. The dose of methadone may need to be increased depending on 
craving and use of illicit drugs over the next weeks. GPs should not prescribe in isolation 
and are encouraged to work with specialist advice. 
It may be that the young person does not need 30 mg daily. Increases in methadone should 
only be given in response to clear withdrawal symptoms and not requests for sedation. 
One should be careful that anxiety symptoms related to the process and the circumstances 
are not judged to be withdrawal symptoms and methadone adjusted upwards. 
Titration for young people should only be undertaken in an environment where there is 
close observation and supervision. Operating a twice daily administration of medication 
allows smaller doses to be given which increases the flexibility of titration. Any observation 
of drowsiness should be responded to by omission of the next dose and formal review. If the 
young person is already prescribed concomitant respiratory depressant drugs then great care 
is needed with slow titration, of perhaps up to 5 mg increments. There should be no 
medication given while drowsiness is observed, medication should be reviewed and urgent 
medical care given as required. 
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6.4 Buprenorphine induction regime 
Buprenorphine is administered as sublingual tablets. Supervision takes at least 10 minutes 
and demands close observation. Supervision, however, is important, as diversion, 
intravenous use and snorting of these tablets have been recorded. Should the tablet be 
injected or snorted the patient’s treatment should be reviewed urgently by the clinical team. 
The review could include ensuring that there is dependence to opioids, a switch to 
methadone to optimise treatment, and increasing the dose if dosage has been insufficient. 
Liver function tests (LFTs) should be undertaken at the beginning of treatment. If normal 
these tests should be repeated periodically throughout treatment, as buprenorphine can 
cause an increase in aspartate aminotransferase (AST) and alanine aminotransferase (ALT). 
If LFTs are abnormal the patient should be investigated for the underlying cause. 
Significant decompensating liver function is a contraindication to its use. 
The young person and their parents/carers (if appropriate) should be informed about the 
different properties of buprenorphine as compared with methadone, especially precipitated 
withdrawal risk. This may exacerbate rather than reduce withdrawal symptoms in the event 
of recent or current heroin or methadone use. Without full discussion of these and other 
properties of the medication informed consent cannot be given. 
To avoid precipitated withdrawal patients should have been heroin-free for a minimum of 
8 hours and methadone-free for at least 24 hours prior to the initial dose of buprenorphine. 
Ideally, they should also be exhibiting clear signs of opioid withdrawal (Royal College of 
General Practitioners, 2004). Precipitated opioid withdrawal, if it occurs, starts within 1–3 
hours of the first buprenorphine dose, peaks in about 6 hours and then subsides. Adjunctive 
therapy may be required such as lofexidine if withdrawals are severe. 
Induction	regime: 
•	� Observe for clear objective withdrawal signs. 
•	� Initiate at least 8 hours after the last heroin dose or 24–36 hours at least after the 
last dose of methadone. 
•	� Full explanation of the effects of the drug to be given. 
•	� Commence on 2–4 mg (2 mg to the younger person with low BMI). 
•	� Titrate the dose on subsequent days, up to increments of 2–4 mg daily. 
•	� Consumption supervised to ensure that the tablet has fully dispersed. 
•	� Adjunctive symptomatic support or additional buprenorphine may be required in 
the early stage of treatment. 
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•	� Ongoing assessment and monitoring and regular clinical review and reassurance 
are likely to improve compliance and retention. 
6.5 opioid detoxification 
Detoxification can be undertaken using methadone or buprenorphine (NICE, 2007d). 
For young people who have a short history of opioid dependence and mild dependent 
symptoms, are under 16 years, and do not wish (and their parents/carers agree) to have 
either methadone or buprenorphine, then detoxification using lofexidine may be the 
treatment of choice. It is recommended if there is unknown tolerance or suspected low 
tolerance to opioids to commence detoxification with lofexidine. 
For all detoxifications adjunctive treatment may be required, though care should be taken 
to ensure that the detoxification regime is at a suitably high level to optimise care for the 
young person. This will include non-drug measures, such as psychosocial support and 
adequate hydration. To alleviate withdrawal symptoms drug preparations, such as 
anti-emetics or anti-diarrhoeal drugs, may be required, though care should be taken 
with interactions and multiple prescriptions. 
Practitioners should be aware that whatever the duration of detoxification, withdrawal 
symptoms may frequently persist beyond the cessation of all medication. It is important 
to provide support for individuals in the first few days after stopping methadone or 
buprenorphine; at this time some individuals may require symptomatic relief which may 
include the use of low-dose lofexidine. 
Detoxification regimes should not be commenced without first explaining the overall aims 
of treatment and the likely process of detoxification. The reduction programme can be 
slowed or stopped at any time; the process should be reviewed regularly, at least twice 
weekly. If there are concerns about increasing withdrawal symptoms the reduction can be 
slowed or dose increased following careful review. 
The length of the process needs to reflect the level of physical dependence, the length of 
time the young person was already on the prescription (if this was so), the age and needs 
of the young person and the wishes of the young person and their parents/carers. 
Some young people may not be able to successfully detoxify from opioids and remain 
opioid-free. In these cases maintenance may be required and can act to help to reduce 
drug-related harm. 
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6.6 Lofexidine detoxification 
Methadone or buprenorphine should be offered as first line treatment in opioids 
detoxification (NICE, 2007d). Lofexidine may be considered in those who do not want 
either of these drugs, want a short detoxification and have mild or unclear dependence. 
The symptoms of withdrawal present earlier and more intensely in the first few days than 
with tapering methadone regimes. It may cause hypotension. 
Detoxification should commence at 0.2–0.4 mg twice a day, increased daily as necessary to 
control withdrawal, in increments of 0.2–0.8 mg daily to a maximum of 2.4 mg a day. 
This regime may need to be adjusted in response to withdrawal symptoms, with higher 
doses needed by some patients in the early stages of opioid withdrawal. Young people are 
more inclined to need lower doses but again there is little evidence on those under 16. 
The dose should be titrated according to withdrawal symptoms with the young people 
frequently assessed and observed. 
Lofexidine	detoxification	regime: 
•	� Observe for withdrawal signs, unless the person has previously been stabilised on 
methadone or buprenorphine. 
•	� Take baseline pulse and blood pressure readings. 
•	� Give a full explanation of the effects of the medication to be given. 
•	� Initial dosage should be 0.2–0.4 mg twice daily. This dose may be increased by 
increments of 0.2–0.8 mg a day up to a maximum of 2.4 mg (12 tablets). 
•	� Monitor blood pressure and pulse frequently for at least 72 hours, or until a 
stable dose is achieved, whichever is longer. 
•	� Stop medication if there is severe bradycardia or hypotension. 
•	� Stabilise at a constant dose for 7–10 days. 
•	� Decrease dose gradually over a period of at least 2–4 days. 
•	� Slow reduction if hypertension occurs. 
•	� Do not prescribe to pregnant or breastfeeding women. 
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table 3: example of approximately 3 week lofexidine detoxification 
three phases of detoxification example dosage total daily dose 
Increase	dosage	according	to	patient’s	 
response	to	a	maximum	of	2.4	mg 
Day	1	0.4	mg	BD 0.8	mg	 
Day	2	0.6	mg	BD 1.2	mg 
Day	3	0.8	mg	BD 1.6	mg 
Day	4	0.8	mg	BD 1.6	mg 
Day	5	1	mg	BD 2	mg 
Stabilise for 7–10 days Days	6–12	1	mg	BD 2	mg 
reduce	speed	of	withdrawal	if	blood	 
pressure	elevates 
Day	13	0.8	mg	BD 1.6	mg 
Day	14	0.6	mg	BD 1.2	mg 
Day	15	0.4	mg	BD 0.8	mg 
Day	16	0.2	mg	BD 0.4	mg 
Day	17	0	mg	BD 0	mg 
6.7 methadone detoxification 
Methadone detoxification should only be commenced after at least a 5 day period of 
stabilisation to ensure that the optimum dose has been reached before considering reduction 
to minimise discomfort. Due to methadone’s long half-life reduction should be relatively 
slow as withdrawal symptoms may take some time to become obvious. 
•	� Explain fully the regime and goals of the detoxification. 
•	� Reduce methadone by 2.5–5 mg every few days (e.g. every 4 days). 
•	� Stop withdrawal and restabilise if the young person recommences illicit opioid 
use, or if there are other signs that they cannot manage the detoxification. 
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table 4: example of 3 week methadone detoxification 
example of approximately 3 week detoxification regime from 30 mg per day 
Day	1	 30	mg 
Days	2–4	 25	mg 
Days	5–7	 20	mg 
Days	8–10	 15	mg 
Days	11–14	 10	mg 
Days	15–17	 5	mg 
Days	18–20	 2.5	mg 
Day	21	 0	mg 
6.8 Buprenorphine detoxification 
Buprenorphine detoxification should only be commenced after at least a 5 day period of 
stabilisation to ensure that the optimum dose has been reached before considering a 
reduction to minimise discomfort. 
For patients who have been stabilised on buprenorphine, a buprenorphine detoxification 
involves a gradual reduction in doses over the course of at least 2 weeks, but it can be up 
to 12 weeks. 
For patients who have been stabilised on methadone, a buprenorphine detoxification should 
not be commenced until the patient has reduced to at least 20–30 mg of methadone a day, 
with a minimum gap of 24 hours between the last dose of methadone and the initial dose 
of buprenorphine, to avoid precipitated withdrawal symptoms. Ideally, the young person 
should be exhibiting some signs of withdrawal prior to initiation of the buprenorphine. 
table 5: Gradual reduction of buprenorphine 
Daily dose Suggested reduction 
16	mg	or	over	 4	mg	every	1–2	weeks 
8–16	mg	 2–4	mg	every	week 
2–8	mg	 2	mg	every	week 
(Guidance	for	the	use	of	buprenorphine,	Royal	College	of	General	Practitioners,	2004) 
Tables 6 and 7 show alternative suggestions for detoxification from a stabilised dose of 8 mg 
of buprenorphine, though these should be tailored to the individual’s needs. 
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table 6: example of 2 week detoxification from 8 mg of buprenorphine 
8 mg buprenorphine approximately 2 week detoxification 
Day	1	 8	mg 
Days	2–4	 6	mg 
Days	5–7	 4	mg 
Days	8–10	 2	mg 
Days	11–13	 0.8	mg 
Days	14–15	 0.4	mg	 
table 7: example of 4 week detoxification from 8 mg of buprenorphine 
8 mg buprenorphine approximately 4 week detoxification 
Days	1–4		 8	mg 
Days	5–8	 6	mg 
Days	9–12	 4.8	mg 
Days	13–16	 2.8	mg 
Days	17–20	 2	mg 
Further	reduction	of	0.4	mg	every	3–4	days 
There is no evidence on which withdrawal regimes are most effective in young people. 
Clinical reports and opinion would suggest that there is an individualised process of 
detoxification that considers the individual needs of the child/young person. NICE (2007d) 
suggests that detoxification should normally be up to 4 weeks in residential settings and up 
to 12 weeks in community settings. Careful thought should be given if considering a shorter 
detoxification. 
6.9 maintenance with buprenorphine or methadone 
It will not be appropriate to detoxify all opioid-dependent young people. Some will have 
severe dependence, a well established history of misuse and/or previous treatment and 
multiple difficulties including mental health problems, and will be at high risk of future 
overdose. These and other factors such as the age of the young person may indicate that 
they may be more suitable for maintenance. The decision as to whether to maintain or 
detoxify should be made by a multi-disciplinary team which includes the young person and 
their parents/carers as appropriate, and in consultation with a specialist. 
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6.10 Continuation of opioid prescription from a custodial setting 
It is important that there is continuity of care from custody to the community particularly 
if the sentence has been short or the young person has been placed on remand and a 
treatment programme may not have been completed. 
Best practice would involve joint working between the community and custodial services 
throughout the custodial stay and especially during assessment and resettlement planning. 
When a custodial establishment requests information or support it is in the best interests of 
the young person for the community service to act quickly and to assist as much as possible 
with the development of the young person’s care plan. Decisions in custody have to be 
made rapidly and speed of response will be important in helping the young person to 
receive continuity of care. Following release from custody, prioritising young people’s 
treatment and arranging an appointment for assessment as soon as possible, preferably on 
the day of release, will help to avoid gaps in treatment and reduce the possibility of relapse 
and risky behaviour. 
Sometimes a young person remanded in custody will be unexpectedly released from court 
and the custodial establishment may not have had the opportunity to put adequate plans 
in place for continuity of care. Where a young person presents to the community service 
following release from custody where no joint working has taken place the following 
procedures will help to ensure safe and consistent care. 
If a young person declares that they are already on a prescription (methadone or 
buprenorphine) the following should be confirmed prior to continuation of this 
prescription: 
•	� that the young person has been receiving methadone/buprenorphine in custody 
•	� that the young person had the full supervised dose of methadone/buprenorphine 
at least within the past 48 hours 
•	� the dose, frequency of administration and treatment plan from the custodial 
service. 
If the above criteria are confirmed with healthcare staff from the custodial setting then 
the prescription should be continued, although caution is always advised until tolerance is 
assured. Young people should be warned against the use of alcohol and other drugs which 
may contribute to an overdose. Previous history of substance use and treatment prior to 
custody should also be considered. 
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6.11 naltrexone induction regime
�
Naltrexone is an opioid antagonist, and can be helpful following detoxification in enabling 
a person to maintain abstinence. It is licensed for oral use in those over 18 years. Due to the 
potential for hepatotoxicity, a liver function test should be organised prior to 
commencement of treatment and repeated during treatment; if there are even minor 
abnormalities this should be discussed with specialist teams and caution should be observed 
when considering the medication for patients with impaired hepatic or renal functioning 
(NICE, 2007b). 
Care should be taken on initiation, as withdrawal would be precipitated in those dependent 
on opioids. It is recommended that naltrexone treatment should not be initiated until a 
patient is 5–7 days clear of heroin or (because of its greater half-life) 10 days clear of 
methadone. A urine/oral analysis should confirm this opioid-free status during these 
abstinent days and on the day of initiation. 
If it is uncertain whether the person has used opiates, then it may be necessary to conduct a 
challenge. Following a negative urine or oral screen, a test dose (e.g. 12.5 mg of naltrexone) 
is given orally and the person is observed over a few hours for withdrawal symptoms. If no 
withdrawal symptoms are observed then up to 50 mg can be prescribed on a once daily 
basis. This drug may be considered for those adolescents who have detoxified from opioids 
as one part of a programme of supervision, which could involve parents/carers providing 
some of the support. 
It is important to ensure that the young person is aware of their loss of tolerance to opioids 
and the risk of overdose should opioids be taken, especially if there is poor compliance with 
the naltrexone regime. 
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7. Prescribing protocols for 
alcohol and non-opioid drugs 
Prescribing protocols for alcohol and non-opioid drugs – key points 
multiple dependences 
•	� Dependence on a combination of alcohol, opioids and benzodiazepines will require 
more than one reduction regime. 
alcohol 
•	� The recommended medication for the treatment of alcohol detoxification is 
chlordiazepoxide. The usual regime will be 20 mg of chlordiazepoxide QDS initially 
and then reducing over 7 days. 
•	� The dose of chlordiazepoxide should be titrated until withdrawal symptoms cease. 
•	� If withdrawal symptoms do not stabilise, or if there are seizures or delirium 
symptoms, the young person should be transferred to a general hospital. 
•	� Acamprosate or disulfiram may have a role, but only where supported by specialist 
community substance misuse teams and the young person’s family/carers. 
Benzodiazepines 
•	� Benzodiazepine maintenance prescribing is not recommended in children and young 
people. 
•	� Detoxification using diazepam should be gradual according to the length and severity 
of dependence. 
•	� Diazepam at 30 mg a day is usually a sufficient maximum detoxification dose, even 
where previous use was higher. 
•	� Benzodiazepine dependence and withdrawal can be associated with suicidal and 
self-harming behaviours. 
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Cannabis 
•	� Withdrawal from cannabis may precipitate decreased appetite, weight loss, sleep 
problems, craving, irritability and vivid dreams. These symptoms may require 
management. 
•	� Cannabis can contribute to and compound mental health problems. Where there 
is any evidence of psychoses a full mental health assessment should be completed; 
anti-psychotic medications may be required. 
Inhalants 
•	� Deaths are mostly related to ‘sudden sniffing’ or accidental injury while intoxicated. 
•	� For very frequent inhalant users withdrawal may precipitate agitation which should 
be monitored as it may require treatment. 
Stimulants 
•	� There is little evidence for the use of pharmacology in the treatment of cocaine or 
amphetamine dependence for adults, and none for children or young people. 
•	� Stimulant withdrawal may precipitate significant psychological symptoms such as 
self-harm and suicide, violence, agitation and depression which may require 
treatment and careful monitoring. 
•	� Psychological symptoms should be managed in tandem with the mental health team 
and include a full mental health assessment. 
7.1 multiple dependences 
Dependence on any combination of alcohol, opioids and benzodiazepine will require more 
than one reduction regime. Prescribing should proceed with additional caution due to the 
interaction of these drugs. 
In the context of opioid and alcohol physical dependence, the opioid regime should remain 
stable while the alcohol detoxification is taking place. For dual alcohol and benzodiazepine 
dependence, clinicians may wish to combine the regimes using an increased level of 
chlordiazepoxide for the first seven days to cover both alcohol and benzodiazepine 
withdrawal regimes, followed by conversion to once daily use of diazepam and a graduated 
withdrawal regime. 
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7.2 alcohol detoxification 
The choice of drug for alcohol detoxification is benzodiazepines, usually chlordiazepoxide or 
diazepam. The benefits of this are: 
• a reduction in the severity of withdrawal 
• a reduction in the incidence of complications 
• a reduction in the adverse effects of medication 
• improved completion rates. 
The British Association for Psychopharmacology guidelines (2004) do not consider the 
choice of benzodiazepine to be crucial though longer-acting benzodiazepines are more 
effective in preventing fits and delirium. Chlordiazepoxide is generally recommended (Royal 
College of Physicians, 2001), though diazepam may be more beneficial if there is a history 
of seizures. Symptoms of withdrawal following diagnoses of physical dependence should be 
treated on an urgent basis. 
The symptoms of alcohol withdrawal include: 
• sweating 
• tremors 
• nausea 
• vomiting 
• hypertension (raised blood pressure) 
• tachycardia 
• agitated states 
• seizures or delirium tremens as complicating factors. 
The severity of dependent symptoms can vary and so affect the amount of benzodiazepines 
required. There are alternative models of delivery of benzodiazepines, such as titration of 
dose against withdrawal symptoms, ‘front loading’ until light sedation is achieved, or fixed 
reducing regime. Some of these regimes require more skilled monitoring and supervision. 
A usual regime is of approximately 20 mg of chlordiazepoxide QDS initially, then reducing 
over about 7 days. This dose should be given on a four times daily basis initially so that 
withdrawal symptoms can be observed and the chlordiazepoxide titrated to the dose 
required. A reduction over 5 days for mild dependence could be: 
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• Day 1 – 20 mg QDS 
• Day 2 – 15 mg QDS 
• Day 3 – 10 mg QDS 
• Day 4 – 5 mg QDS 
• Day 5 – 5 mg BD 
or gradations similar to this reduction (Parker et al, 2008). 
The regime should be closely monitored, with a reduction of dose if there is evidence of over-
sedation. There is little evidence on dose requirements for children and young people. While 
the dose of 20 mg QDS may be appropriate for a young person with mild dependence, it is 
important to be aware that, though unusual, severe dependence may occur with the need for 
increased doses that are titrated against increasing withdrawal symptoms. If vomiting is 
persistent hospitalisation should be considered as parenteral sedation may be required. For those 
who have a diagnosis of epilepsy and are prescribed anti-convulsant medication this should be 
stabilised, with careful monitoring. Advice from neurological services may be required. 
It is important that individuals are monitored by specialist staff at least daily for the first 
seven days of their management because of possible seizures, or symptoms of co-existing 
illness that interferes with diagnosis, such as anxiety disorder or head injury. The setting for 
detoxification should be decided on the severity of dependence, other physical concomitant 
difficulties, availability of support and observation required. Parents/carers should be 
provided with full information on possible side effects, overdose and how to gain help 
should they have concerns about their child’s well-being. 
Where concurrent opioid detoxification is indicated, no reduction in methadone or 
buprenorphine should be attempted until the alcohol detoxification is complete. 
7.2.1 Complications 
If a young person continues to demonstrate signs of alcohol withdrawal during 
detoxification additional doses of chlordiazepoxide or diazepam should be given. Should a 
patient’s condition not stabilise, they should be urgently transferred to a hospital, as this is 
a potentially fatal condition. 
Benzodiazepines, particularly diazepam, reduce de novo seizures and are recommended for 
treatment of withdrawal previously complicated by withdrawal seizures. Lorazepam is 
considered efficacious in preventing a second seizure in the same withdrawal episode. 
The evidence does not support the use of phenytoin in this circumstance (British 
Association for Psychopharmacology, 2004). Carbamazepine is also effective in both 
management of withdrawal symptoms and in management of seizures (British Association 
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for Psychopharmacology, 2004). However, the use of benzodiazepines is advised as 
the treatment of choice in the management of alcohol withdrawal. Chlormethiazole is not 
recommended for use in alcohol withdrawal in younger people. 
Longer acting benzodiazepines help to prevent delirium and are recommended for this 
complication of alcohol withdrawal. However, should the young person have delirium 
symptoms, then they should be urgently transferred to a hospital. 
Should the young person have delirium symptoms, symptoms of Wernicke’s 
encephalopathy or even some symptoms suggestive of this, they should be urgently 
transferred to hospital. (Wernicke’s encephalopathy presents with the full classical triad 
in only 10% of adults dependent on alcohol.) 
7.3 alcohol relapse prevention 
Acamprosate can be used to improve abstinence rates and reduce drinking days and craving, 
though there is no clear evidence on which type of person might benefit. In adults 
acamprosate is recommended for those attempting to maintain abstinence when combined 
with psychosocial treatments. For those under 18 with alcohol dependence acamprosate is 
not recommended unless there is clear involvement with community specialist teams. 
However, there are some early positive suggestions for the use of acamprosate in adolescents. 
With regard to disulfiram, despite its use for many years, there have been few controlled 
trials. Supervised consumption of this drug may improve efficacy. When prescribed without 
this supervision, there is little evidence for effectiveness above basic support. Care should be 
taken on initiation of this prescription as a young person may binge drink on discharge, 
without consideration of the consequences of the use of this drug. For those young people 
with dependence disulfiram is not recommended for use without the full involvement of 
community specialist teams, and parents/carers may be useful in terms of supervision of 
these drugs and support. 
Naltrexone is not licensed for use in those with alcohol difficulties. 
7.4 Benzodiazepine detoxification 
Benzodiazepine withdrawal symptoms may take more than 72 hours to become established; 
a negative urine/oral fluid result would be unusual in a young person with physical 
dependence but should not automatically preclude the need for management of this 
dependence pharmacologically. There may be reasons why the young person could not gain 
access to illicit supplies in the previous few days, which should be considered (e.g. time 
spent in police custody). However, only a minority of young people who misuse these drugs 
develop dependence (Ross and Darke, 2000). 
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Where physical dependence is established, either from illicit use or prescription for anxiety 
states, gradual discontinuation is recommended. There is little evidence that long-term 
prescribing of benzodiazepines reduces the harm associated with benzodiazepine dependence 
and increasing evidence that long-term prescribing may cause harm. Maintenance is not 
recommended in children and young people. 
Where clinical assessment indicates a previous history of regular benzodiazepine use 
sufficient in dose and duration to suggest dependence, a benzodiazepine detoxification 
regime should be prescribed. Diazepam is licensed for the management of benzodiazepine 
withdrawal. 
Detoxification should be initiated where there is a history of benzodiazepine physical 
dependence, and observed objective withdrawal symptoms. It is important to note that, 
depending on the timing of ingestion of last dose and assessment, withdrawal may not 
present, so it is important to continue monitoring for withdrawal signs. However, even if 
the young person reports the historical use of very large amounts of benzodiazepines, 
evidence suggests that prescribing need only be in moderate doses, often far lower than the 
previously stated dose. The lowest dose to prevent withdrawal should be used (Department 
of Health, 1999). 
Diazepam is the drug of choice as it has a long half-life, can be given in daily doses and is 
helpful in preventing seizures, and tablets are available in various doses. For those already 
prescribed both diazepam and a hypnotic such as temazepam, it is advisable to convert all 
benzodiazepines to diazepam; this can be approximated from equivalents charts 
(Department of Health, 2007). For example, 5 mg of diazepam is roughly equivalent to 
15 mg of chlordiazepoxide and 10 mg of temazepam. 
The dose for initiation to ease withdrawal symptoms is unlikely to exceed 30 mg. If there 
is a need for larger doses then the young person should be frequently reviewed by a doctor 
or non-medical prescriber and multi-disciplinary team. 
Diazepam should initially be prescribed in divided doses titrated against withdrawal 
symptoms for the first seven days. Reduction or omission of dose should occur if there is 
any evidence of sedation and the patient should be reviewed prior to reinitiation of the 
prescribing regime. 
There is no clear guidance on the rate of withdrawal. The withdrawal regime will depend 
on a number of factors: severity of dependence, age of the individual, body weight, history 
of tolerance, history of prescribed use of benzodiazepines, reason for any previous 
prescriptions, and use of or dependence on illicit drugs or alcohol. 
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If the young person is receiving a prescription for opiate dependence at the same time, 
the methadone or buprenorphine dose should be kept stable while the benzodiazepines are 
being reduced. For those with dependence on both alcohol and benzodiazepines, the 
withdrawals should be managed with chlordiazepoxide initially. Chlordiazepoxide should be 
initiated, increasing the dose to manage both dependences, and then reducing over a period 
of days (administered QDS); this will manage the alcohol withdrawal. The chlordiazepoxide 
should then be converted to diazepam for a once daily dose and gradually reduced to 
manage the benzodiazepine dependence. 
Benzodiazepine withdrawal should be gradual. The Department of Health (2007) suggests 
withdrawal in proportions of about one eighth of a daily dose once a fortnight, or for those 
with dependence on therapeutic doses, clinicians suggest 2 mg per week which should be 
reviewed if withdrawal symptoms occur. Suggestions for rate of withdrawal include 2–4 mg 
per week, or 5–10 mg per month. The rate of withdrawal is often determined by the 
individual’s capacity to tolerate symptoms. However, the rate should be partly determined 
by the level of severity of dependence on the drug and length of use. 
Longer-term prescribing and gradual withdrawal of benzodiazepines should adhere to the 
general principles of management: clear indications of dependence, clear intermediate goals, 
regular review and methods to prevent diversion (Department of Health, 2007). 
Benzodiazepine dependence and withdrawal can be associated with suicidal and 
self-harming behaviours, and should be managed accordingly with due caution, and 
may require a slow reduction and psychological support. 
Young people with a confirmed history of epilepsy will require cautious rates of reduction 
for benzodiazepine dependence, informed by ongoing monitoring. A review of any currently 
prescribed anti-convulsant medication should be organised, with advice from specialist 
if required. 
7.5 Cannabis 
Cannabis dependence is reported in regular users, with characteristic withdrawal symptoms 
apparent on sudden cessation. This syndrome can last between 10 days and several weeks 
and may be associated with decreased appetite, weight loss, sleep problems and craving as 
well as irritability, aggression and vivid dreams. These withdrawal symptoms may need 
supportive management. 
Cannabis may both precipitate psychoses in young people and impact negatively on those 
with mental health problems. Among young people with psychoses such as schizophrenia, 
chronic cannabis use negatively impacts on course and treatment of the illness, and is 
associated with poor compliance with medication and earlier and more frequent relapses. 
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There is increasing interest in drug-induced psychoses caused by cannabis and its 
relationship with long-term psychotic illnesses. A number of studies have demonstrated 
that young cannabis users are at least 2–3 times more likely to demonstrate psychotic 
symptomatology; it appears that this primarily relates to the precipitation of psychoses in 
vulnerable groups. Management of drug-induced psychoses requires urgent treatment with 
anti-psychotic medications and close working with the CAMHS team. It is crucial that 
young cannabis misusers with dependence are monitored, with their mental state carefully 
assessed. Psychosocial treatments should be given to those with cannabis misuse in line with 
the NICE (2007e) and NTA (2008b) guidelines. 
7.6 Inhalants 
Young people may abuse these drugs as they are cheap and easily available and provide rapid 
intoxication. There are a wide range of household and commercial products that fall into 
this category. This intoxication is similar to that of alcohol, with symptoms of euphoria, 
disinhibition and excitement leading to disorientation and short-acting central nervous 
system depression. Deaths are related more often to ‘sudden sniffing’ or accidental injury 
while intoxicated. Evidence of inhalant physical dependence is limited with case reports 
suggesting a withdrawal syndrome similar to alcohol withdrawal. Physical symptoms are 
usually short-lived, though agitation and craving may continue for weeks. It is 
recommended that inhalant users are routinely assessed, and if intoxicated the young person 
may need unrestricted observation for some time. 
There is no specific pharmacological treatment recommended but support and symptomatic 
treatment may be required in the short term for agitation. Clearly, a comprehensive 
assessment of all needs should be conducted accompanied by the development of a care plan. 
7.7 Stimulants 
The mainstay of treatment for stimulant users is psychosocial approaches with little 
evidence for pharmacological approaches. Research on pharmacology has mainly 
concentrated on withdrawal and the maintenance of abstinence. The evidence for 
pharmacological approaches is scanty at best. Likewise, while psychosocial interventions are 
considered the mainstay of treatment, there is also a lack of good quality research and 
reviews in young people. 
For those with cocaine dependence, there has been much interest in anti-depressants, 
disulfiram, carbamazepine, dopamine agonists, dexamphetamine and other drugs, such as 
phenytoin and naltrexone. To date there is little evidence to support the use of these 
pharmacological agents, with no evidence for their use in young people. 
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Similarly for those with amphetamine dependence there is no clear evidence to support 
substitute medication at present. At this stage, there is no evidence to support the use of 
any pharmacological drugs to effect withdrawal or substitution for cocaine or amphetamine 
dependence in children and young people. It is important to consider that, like other young 
people who use illicit drugs and alcohol, those using stimulants may use many other 
substances, e.g. cannabis, alcohol and ketamine. 
Psychosocial interventions, an abstinence-based approach linking counselling and social 
support, have the greatest impact on cocaine misuse with approaches incorporating 
contingency management found to be successful (Department of Health, 2007 and NICE, 
2007e). However, there is a dearth of well evidenced therapies in the younger age group. 
Nevertheless, a young person may have problems on withdrawal of stimulants, particularly 
if admitted to a custodial setting and this needs careful monitoring and management 
(British Association for Psychopharmacology, 2004).
A young person with stimulant withdrawal may present with problems related to mood 
changes, suicidal and self-harming behaviours, possible violence/psychoses and significant 
agitation. A short but profound depression is a recognised withdrawal symptom, which may 
necessitate treatment. There is no evidence that anti-depressants can ameliorate the 
withdrawal effects by stimulants (Department of Health, 2007). Sudden death occasioned 
by an intracranial bleed or cardiac arrest appears to be an increasing risk among young 
people abusing crack. 
It is recommended that young people reporting recent heavy stimulant use and whose 
urine/oral fluid tests are positive for stimulants are monitored for signs of hypertension 
and neurological problems. Any abnormalities would warrant full medical assessment, 
and in the event of continued concern, transfer to a general hospital. 
Where there is evidence of agitation or volatility in those withdrawing from stimulants 
stress reduction procedures may benefit the young person. There is no evidence to prescribe 
benzodiazepines though a short regime of diazepam may be required for extreme agitation 
(Department of Health, 2007). A psychosis related to stimulant abuse needs careful 
assessment and management, probable anti-psychotic medication with close review and 
involvement of the CAMHS teams. 
At the same time there needs to be observation for a co-existing mental illness, change in 
mood or behaviour related to withdrawals, or use of drugs precipitating and exacerbating 
other mental illnesses. A full mental health assessment should be considered for any young 
person demonstrating symptoms/signs of any of these problems. Concerns for the young 
person’s safety as a result of their mental distress should result in appropriate action to 
reduce risk. 
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All those with stimulant-related problems should have this full assessment with a 
comprehensive plan in place, particularly with regard to psychosocial treatments and family 
therapies, details of which can be found in NTA (2008b). 
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disorders 
management of co-morbid disorders – key points 
•	� A high percentage of young people with substance misuse problems will have a 
co-morbid disorder, for example substance misuse and depression. 
•	� Substance misuse may contribute to or exacerbate mental illness; symptoms of 
mental illness are common. 
•	� Any mental health diagnosis and consideration of treatment should be in 
conjunction with CAMHS and substance misuse services. 
•	� Clear transfer arrangements should be in place for those leaving a custodial setting 
with co-morbid substance misuse and mental health problems (dual diagnosis). 
•	� Psychological interventions are the mainstay of mental health management in 
children and young people, but pharmacology may be required. 
•	� Physical health problems should be considered as these may have been exacerbated 
by substance misuse, or their treatments contraindicated with regard to substance 
misuse pharmacology. 
•	� It is vital that pregnancy is identified and the implications taken account of with 
regard to substance misuse pharmacology and the care and safety of the mother 
and child. 
•	� Specialist substance misuse treatment providers are encouraged to work closely with 
youth justice agencies, including YOTs and custodial establishments, to develop 
joint working arrangements and care plans for young people. 
The successful treatment of substance misuse disorders is likely to involve the use of 
multiple treatment interventions, related to the high prevalence of co-morbid disorders 
in this population, combined with multiple social difficulties. 
The term ‘dual diagnosis’ is used to describe the co-existence of psychiatric disorders and 
substance misuse. Many young people with a substance misuse disorder have pre-existing 
impulsive, oppositional and conduct disorder behaviours with others reporting anxiety and 
depressive disorders. Approximately 30–50% of substance misusers have psychiatric 
disorders, and approximately 30–50% of young people with psychiatric disorders, especially 
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disruptive behaviour disorders, have substance misuse problems. Psychiatric disorders, that 
begin in childhood have a strong likelihood of continuing into later life, and may be further 
complicated by substance misuse. Affective disorders, personality difficulties and attention 
deficit hyperactivity disorder can all be associated with substance use. Substance misuse is 
also a powerful predictor of suicide. 
8.1 mental health 
Symptoms of mood disorder, anxiety and psychosis are common in those who misuse 
alcohol and drugs. Chronic use, intoxication and withdrawal can produce symptoms similar 
to anxiety and depression, precipitate panic disorders, agitation and extreme irritability, and 
may mimic a schizophrenia-like illness. In addition those with pre-existing mental health 
problems are at higher risk of substance misuse, with withdrawal symptoms possibly 
exacerbating the pre-existing mental illness. 
Young women in custody are likely to be highly vulnerable to mental health problems 
especially in relation to post-traumatic stress disorder, depression, suicide and self-harm 
(Douglas and Plugge, 2006 and Galahad, 2004). Other studies suggest that, among young 
people being treated for substance misuse, young women will have more severe mental 
health problems than young men (Ruiz et al, 2005). 
An assessment should be conducted which should include: 
•	� a complete history of substance use with toxicology and corroborative evidence 
where possible from community teams and parents/carers 
•	� a mental health assessment which includes persistence of mental health symptoms 
during substance use, abstinence and response to previous treatments. 
Those undertaking a comprehensive co-morbidity assessment, treatment, anti-psychotic 
medication, substance misuse medication and other pharmacological treatments should all 
be discussed and a treatment plan arrived at as part of a multi-disciplinary/agency approach 
involving CAMHS and substance misuse specialists. 
A pragmatic and integrated approach should be taken with treatment of both disorders 
concurrently, using both psychosocial and pharmacological approaches if necessary in 
liaison with CAMHS to produce a clear care plan. There should be clarity about the 
responsibilities of CAMHS and the substance misuse team and care should be taken to 
avoid any separation between substance misuse and mental health teams that might lead 
to confusion of role with inadequate assessment, treatment and follow-up plans. 
Commissioners in community settings should also be aware of the high prevalence of 
co-morbid disorders, particularly in young offenders. Appropriate arrangements for shared 
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care between specialist community drug services and CAMHS should be recognised and 
put in place to ensure fast and accessible treatment on discharge from custody. 
Psychosocial interventions are the mainstay of treatment. Management of mood and anxiety 
disorders with pharmacological interventions is generally not recommended in young people 
(NICE, 2005). Mood disorders should be observed carefully, and mood may improve 
with management of the dependence and withdrawal symptoms. Advice and assessment 
from CAMHS should be sought. 
8.2 Physical health 
Young people may have physical difficulties, e.g. diabetes, asthma, obesity and infections 
that will need assessment and treatment. Some young people may have sexually transmitted 
infections that need to be identified and treated. Young people will benefit from a baseline 
physical assessment (all with informed consent), and advice and support on all physical 
health needs, including sexually transmitted infections. 
It is important that all those with a history of intravenous drug use are assessed for 
blood-borne viruses. This is particularly important given the high prevalence of some 
blood-borne viruses, and testing should be done with full consent. Young people who are 
injecting drug users or living in close contact with injecting drug users should be 
encouraged to take up offers of hepatitis B vaccination. 
If a young person is receiving treatment for HIV or hepatitis C, then it is important that 
the substance misuse specialists liaise closely with the infectious disease team, particularly 
as some medications may interact with methadone. 
8.3 Pregnancy 
It is important that pregnancy is considered in all young women. Some may be unaware 
that they are pregnant because amenorrhea is common and withdrawal symptoms may 
mimic signs of early pregnancy. All should be encouraged to have a pregnancy test. If a 
woman is considering termination, or miscarries, counselling needs to be given and 
appropriate drug treatment maintained until she recovers (Department of Health, 2007). 
The management of those young women who are pregnant should be carefully planned, 
and managed within a multi-disciplinary team. Antenatal care is important with advice 
and management of all risks such as smoking, nutritional status, and management of 
alcohol and other drugs. Guidelines are available for the management of substance 
misuse in pregnancy (Department of Health, 2007 and British Association for 
Psychopharmacology, 2004). 
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Drug and alcohol and obstetric services should provide an integrated service and develop a 
joint care plan. Good co-ordination will provide better services for the young woman and 
the unborn child. Child protection for the unborn child should be considered and indeed 
for the young woman. 
For those who are pregnant and alcohol dependent, benzodiazepines are the drug advised 
but the lowest doses should be used to avoid potential teratogenicity (British Association for 
Psychopharmacology, 2004). Medication for relapse prevention (e.g. acamprosate) should 
be avoided. 
For those with opioid physical dependence, methadone is the drug recommended for the 
management of opioid dependence in pregnancy. Methadone maintenance combined with 
antenatal care can result in significant improvement in the health of the young woman and 
the foetus. There appears to be no adverse effect on the foetus or young woman, with 
improved birth weight being found, though the neonatal withdrawal syndrome should be 
anticipated and carefully managed. 
In line with the Department of Health (2007) guidelines, the overall evidence indicates 
that methadone at a dose that stops or minimises illicit use is most appropriate for ensuring 
continuity of management of pregnancy and aftercare. This principle applies to all pregnant 
women though there is little evidence available to guide the clinician specifically in 
the adolescent. 
For those considering detoxification it is advised that during the first trimester the person 
should be stabilised. The middle trimester is considered the most appropriate, with 
reduction of methadone in small, frequent reductions of 2–3 mg of methadone every 
3–5 days as long as opioid use is not continuing; during the third trimester methadone 
metabolises more quickly and should therefore be stabilised, or increases in dosing and/or 
frequency of dosing may be required (Department of Health, 2007). However, stability 
with no illicit use is the main goal of treatment. Should there be any illicit use, then 
increase in dose or cessation of this slow reduction regime should be considered. 
8.4 Young offenders 
Some young people who offend may not have previously engaged with substance misuse 
treatment services before they have had contact with the youth justice system. They may be 
wary of interventions and need support to help them to understand the treatment options 
available to them and the benefits and risks associated with each. 
Specialist substance misuse treatment providers are encouraged to work closely with youth 
justice agencies, including YOTs and custodial establishments, to develop joint working 
arrangements and care plans for young people. 
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The Youth Justice Board is actively promoting a system of seamless continuity of care from 
community to custody and back to community. Community services can contribute to this 
by proactively working with custodial establishments to help young people to receive the 
best possible care and ensuring that any progress made in custody is not lost when the 
young person returns to the community. 
Custodial establishments have received guidance and encouragement to provide a range 
of pharmacological management responses to substance misuse needs which match closely 
with this guidance to help promote continuity of care. Community providers can check 
with local establishments to determine what interventions are offered and if there are 
opportunities for joint development initiatives. Some young people will be placed in 
custodial establishments outside the local area and while this may make contact with the 
establishment more difficult every effort should be made to do so. Technology such as video 
or telephone conferencing could be used to help to facilitate this; some YOTs have access to 
this technology and may be able to assist in facilitating it. 
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appendix 1: Parental 

responsibility holder
�
the Children act 1989 sets out who has parental responsibility: 
•	� The child’s parents, if married to each other at the time of conception or birth. 
•	� The child’s mother, but not the father if they were not married, unless the father 
has acquired parental responsibility via a court order or a parental responsibility 
agreement or the couple subsequently marry. 
•	� The child’s legally appointed guardian – appointed either by a court or by a 
parent with parental responsibility in the event of their own death. 
•	� A person in whose favour a court has made a residence order concerning the child. 
•	� A local authority designated in a care order in respect of the child (but not where 
the child is being looked after under section 20 of the Children Act 1989, also 
known as being ‘accommodated’ or in ‘voluntary care’). 
•	� A local authority or other authorised person who holds an emergency protection 
order in respect of the child. 
•	� Foster parents, step-parents and grandparents do not automatically have parental 
responsibility. 
(Department of Health, 2001, Seeking consent: working with children) 
the Children act 2004 sets out the parental responsibility for unmarried fathers: 
Unmarried fathers do not have automatic parental responsibility. Unless they have 
registered or re-registered their names on their children’s birth certificates after 1 December 
2003, in which case they will have parental responsibility for their children. Therefore: 
•	� If an unmarried father has a child after 1 December 2003 and is registered on the 
birth certificate, he will have parental responsibility. 
•	� If a child was registered before 1 December 2003 and the father was not named 
on the birth certificate, the child can be re-registered to include the father’s name. 
Once this has been done, the father will have parental responsibility. 
•	� If an unmarried father’s name is already on the birth certificate and the child was 
registered before 1 December 2003, the law has not changed this situation so the 
father will not have parental responsibility (unless obtained by other means). 
(Children’s Legal Centre, 2006) 
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The following list shows substances according to three categories: depressants, stimulants 
and hallucinogens. Many young people take more than one drug at the same time, which is 
known as poly-drug use. Combining substances in the same category will increase the effect, 
and in the case of depressants is strongly linked to overdose. Combining substances from 
different categories can have an unpredictable effect. 
Substances are often known to young people by their street name. These have not been 
reproduced here, as professionals are encouraged to use the correct terminology to help 
young people understand the substances they have taken. There are a large number of 
street names that regularly change, are affected by fashions and have regional variance. 
For comprehensive information about street names and effects of substances, go to 
www.talktofrank.com 
table 8: action of substances on the central nervous system 
Depressants Stimulants Hallucinogens 
•	opioids	–	 
heroin	(street	names	 
include:	brown,	smack,	H),	 
methadone,	 
buprenorphine,	 
dihydrocodeine,	codeine 
•	alcohol 
•	Benzodiazepines – 
diazepam,	temazepam 
•	 Inhalants –	solvents,	gas,	 
glue	and	aerosols 
•	tobacco 
•	Cocaine –	crack 
•	amphetamine 
•	ecstasy –	MDMA	 
(methylenedioxy-
methamphetamine) 
•	Cannabis	(also	has	a	 
sedative	effect) 
•	LSD 
•	magic mushrooms 
•	Ketamine	(also	has	an	 
analgesic	effect) 
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Legislation that directly addresses equality 
The Race Relations (Amendment) Act 2000, which amends the 1976 Act, prohibits race 
discrimination by placing a duty on public authorities (or bodies providing public services) 
to eliminate race discrimination, promote equality of opportunity, promote good relations 
and have systems in place to meet these obligations. 
The Sex Discrimination Act 1975 (as amended) prohibits discrimination on the basis of sex 
and places a duty on public authorities to proactively promote equality. It is permissible for 
a service to be delivered separately for either sex where this is the most effective way for the 
service to be delivered, as in the case, for instance, of victims of sexual abuse. 
The Disability Discrimination Act 1995 (as amended) offers similar protection to people of 
all ages with disabilities as are offered under the Acts described above. It also places similar 
obligations with regard to people with disabilities on public authorities or private bodies 
delivering public services. 
The Equality Act 2006 outlaws discrimination on the basis of religion or sexual orientation 
in the provision of goods, facilities and services. It complements the Employment Equality 
(Religion or Belief) Regulations 2003 and the Employment Equality (Sexual Orientation) 
Regulations 2003, which make it unlawful for employers to discriminate on the basis of 
religion or sexual orientation. 
Other legislation which, while not being directly relevant to this guidance, may have an 
impact on the agencies involved in the delivery of clinical services, includes: 
• the Gender Recognition Act 2004 
• the Sex Discrimination (Gender Reassignment) Regulations 1999 
• the Equal Pay Act 1970 (as amended) 
• the Civil Partnership Act 2004. 
Local planning and delivery 
Local areas are responsible for meeting the needs of all communities and should be aware 
that the provision of universally available services does not necessarily, by itself, meet those 
needs. There may be cultural or practical impediments to members of different 
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communities approaching mainstream services for help. Service providers have a duty to 
tackle this discrimination proactively. 
For many areas, existing sources of information may be insufficient for the effective 
planning of clinical services to young people. This may be the case where, for example, a 
specific group is under-represented in treatment or access to other services, or where there 
has been significant demographic change. Commissioners and providers of clinical services 
should therefore consider putting in place systems to determine the baseline level and 
nature of needs, and should plan and deliver services accordingly. However, where data and 
information are not available at a local level, this should not inhibit the provision of 
appropriate services to meet assumed or anticipated needs. The extent to which this 
provision meets the needs of all communities should be monitored, and this information 
should inform ongoing delivery. 
Commissioners and providers of services should consider the following key equality issues: 
•	� access to comprehensive services to young women with children 
•	� the provision of culturally competent services, including meeting language needs 
•	� sensitivity to the wider issues of sense of self, particularly for young people of 
dual heritage 
•	� the complex needs of service users with learning difficulties1,2 
•	� providing family-based services which address the needs of all families, as most 
widely defined 
•	� investigating the means by which information might be obtained to determine 
patterns of drug use and service needs, particularly where there are significant 
gaps in evidence, such as the needs of lesbian, gay, bisexual, and transsexual 
young people (www.cypf.csip.org.uk/camhs). 
1	 Taggart	L,	Mc	Laughlin	D,	Quinn	B	and	Milligan	V	(2004),	An Exploration of Substance Misuse 
in People with Learning Disabilities Living within Northern Ireland,	University	of	Ulster. 
2	 Care	Services	Improvement	Partnership	(2007),	Positive Practice, Positive Outcomes: 
A Handbook for Professionals in the Criminal Justice System working with Offenders with 
Learning Disabilities. 
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